470 Comments

It's interesting that the person in charge of the executive branch cannot direct or in any way influence the executive branch's decisions. You can argue that he shouldn't to preserve their integrity, but still it's interesting.

Expand full comment

Or Congress for that matter. They could amend whatever law says "it's illegal to distribute a drug that's not approved by the FDA" to say "it's illegal to distribute a drug other than Paxlovid that's not approved by the FDA", couldn't they? Hungary did something like this with Russian and Chinese COVID vaccines.

Expand full comment

I mean, Hungary didn't amend the law in this manner, but just changed the law governing how the FDA-equivalent is supposed to decide approvals in such a way that it effectively required it to approve those vaccines, which it did.

Expand full comment
Comment deleted
Expand full comment

Your photos get 4/5 from me

Expand full comment

Well, I think it is reassuring. Imagine the outcry if Trump had personally approved $drugname as COVID treatment. In the worst case the US drug market would be split into republican-approved and democratic-approved drugs...

Expand full comment

Imagine the studies that could be done!

Expand full comment

This is the right take. There are still a few areas of the government that the average person doesn't believe is in bed with one of the tribes. Could you imagine the distrust we would have on a grand scale if we lose that?

Expand full comment

If Biden strong-armed the FDA to approve paxlovid right now, that would (allegedly) save approximately 50,000 lives. I'm reluctant to kill 50,000 people in exchange for some nebulous notion of distrust.

Expand full comment

> some nebulous notion of distrust

The lack of trust in institutions has been real and had real-world damage done to the country.

Expand full comment

Exactly. The 50,000 people who are going to die if we don't push out Paxlovid are mostly dying due to institutional distrust. In September 1,800 people died a day and 90%+ of them were unvaccinated.

Expand full comment

I don't believe that figure is correct. It is difficult for me to find the numbers, since the CDC and others are reporting elusively in terms of death rates of the vaccinated vs unvaccinated, and I my numeric literacy is not enough to work out the actual figures.

So looking at September, if 1,800 people died, and the death rate for the vaccinated is 0.86 per 100,000 and the death rate for the unvaccinated is 11.51 per 100,000, and the US vaccination rate is 57.8%, how many of the 1,800 who died were vaccinated and how many were unvaccinated?

I don't think the answer is 180 vs 1,620, but I don't know.

Expand full comment
founding

There's nothing nebulous about the difference between high-trust and low-trust societies, and preserving social trust is definitely worth 50,000 lives. Whether the particular increment of social trust that would be burned by openly politicizing an FDA drug approval is valuable at that level is not obvious. But we've been burning an awful lot of social trust in this pandemic, mostly for the sake of hamfisted interventions that did little if any good. So I'm going to push back on "to hell with that namby-pamby 'social trust' thing, we're saving *lives* here!" when I see it.

Expand full comment

As opposed to the world we live in where Trump developed vaccines at "warp speed" and now Republicans strongly support those vaccines and don't spread anti-vaxx nonsense online.

Expand full comment

The main limitation on something like the capacity of the FDA is funding, and that's controlled by congress.

Expand full comment

I am not persuaded that designing cost effective regulations is much more costly than non-cost effective ones. I do not think funding explains failings in general and it sure does not explain Paxlovid.

Expand full comment

the FDA is funded by the drug companies- to the tune of approx. 45% of its budget. it has been this way since 1992.

Why is the FDA Funded in Part by the Companies It Regulates?

Nearly half the agency's budget now comes from 'user fees' paid by companies seeking approval for medical devices or drugs

source: https://today.uconn.edu/2021/05/why-is-the-fda-funded-in-part-by-the-companies-it-regulates-2/

relevant text:

"In 1992, in response to intense pressure, Congress passed the Prescription Drug User Fee Act. It was signed into law by President George H.W. Bush.

With the act, the FDA moved from a fully taxpayer-funded entity to one funded through tax dollars and new prescription drug user fees. Manufacturers pay these fees when submitting applications to the FDA for drug review and annual user fees based on the number of approved drugs they have on the market. However, it is a complex formula with waivers, refunds and exemptions based on the category of drugs being approved and the total number of drugs in the manufacturers portfolio."

Expand full comment

I do not see a straight line from how FDA is funded and its suboptimal procedures.

Expand full comment

Especially since you'd expect funding from pharma companies to lead to more approvals?

Expand full comment

I'll just say again, I do not see how reformed procedures would be much affected by the level or source of FDA funding. HCT would be less expensive, for example although yes larger trials to test various dosing strategies would, somewhat. And what did the funding have to do with the agency's reluctance to approve quick and dirty screening tests?

Expand full comment

The booster decision was interesting in this respect. If Biden had his way, boosters would have been rolled out for all in mid-September.

Expand full comment

The EUA legislation vests the power in the HHS Secretary (https://www.law.cornell.edu/uscode/text/21/360bbb-3).. HHS policy from a few years ago delegates it to the FDA Commissioner who has delegated it to the heads of CDER / CBER. So it's delegated currently to lifelong FDA bureaucrats who have been selected for and conditioned to have the exact wrong mindset that we need to save lives here.

Last year, around August there was a media backlash after it was revealed the Trump admin was putting pressure on HHS to EUA Pfizer's vaccine in early Nov before the election, an action which back-of-the-envelope calculations suggest would have saved ~10,000 lives.

Whether the president alone can do an EUA on their own is a bit murky (from what I've read probably not? or if they did there would be huge legal challenges). However the president could definitely fire the current HHS secretary and put someone in who would do an EUA.

Expand full comment

Governance of arms-length bodies is an interesting concept.

Counterpoint: Parliament allowed the UK government to relax the normal procurement rules to deal with the crisis and it's argued that they used this power to award contracts corruptly.

https://www.bbc.co.uk/news/56174954

Expand full comment

In your PPPS, you're comparing the reward of saving COVID deaths, vs the risk of you looking like an idiot.

This is extremely inaccurate, the real fear is: the reward of saving COVID deaths, vs the risk of cancer deaths / a higher rate of miscarriages / heart disease / whatever else can go wrong.

The latter aren't things you can say "I accept this risk" about... until you're appointed as Tsar :)

Waiting may mean more people die of COVID-19, but that is happening anyway. It also means that they have a greater chance of catching any horrible unintended side-effects that only manifest over time, which may not only counterbalance COVID deaths saved, but might turn more people against "the medical system" in general, leading to higher mortality.

Expand full comment

If rare side effects are the worry, they should have continued the trial and let it expand to 3,000 people. I can't think of any conceivable rationale for ending the trial but delaying approval.

Expand full comment

I agree with this! The trial should have continued, and in hindsight Pfizer was stupid for stopping it (unless it was forced on them by the FDA).

Expand full comment

What's the difference with giving the drug to the control group in this study, verse when they did the same with their vaccine (at the 3 month point in time into a six month study)?

Expand full comment

No. The trial cannot continue just because there is SOME small chance of rare side effect. There must be equipoise. Trial participants are not LITERALLY guinea pigs

Expand full comment

People in the control group are no worse off than the rest of the population who also doesn't get the drug.

Expand full comment

Ethics boards have made some odd decisions.

The idea that it is unethical to continue a trial once the preliminary results are in if those results show a large enough benefit means that it is more or less impossible to find even somewhat rare side effects until after the drug has been on the market for some time.

The people who are then affected are necessarily not in the trial, i.e. they didn't sign up to be experimented on.

Expand full comment

Assuming the drug is actually that effective in preventing deaths/hospitilizations from a disease that is currently causing huge amounts of deaths and hospitalizations, while in the trial of over 1k but less than 3k people found no serious/obvious side effects... even assuming it's as carcinogenic as smoking cigarettes for a decade, it would be worth giving to anyone presenting covid symptoms.

Expand full comment

Like I have a hard time exagerrating how good the initial trial results were. Its more like being shot and and offered a choice of standing in the open vs. hiding in a concrete bunker with no windows, but there might be some poisonous insects you can't see lurking in the corner.

Nothing is without risk, but some risks are stupider than others

Expand full comment

I'm not sure that the decision point for discontinuing the trial and the decision point for approving the drug should necessarily be the same thing.

Trials test for both efficacy and safety. There might well be a point at which you can say "OK, we have enough signal to know there's efficacy, but we need to observe all the already-dosed patients for another two months to check if any side effects pop up".

(This isn't necessarily what's going on here, I'm sure there's an element of bureaucratic inertia too, and of "Doing things the right way is more important than doing them quickly")

Expand full comment

Depends on the situation. In the setting of a global pandemic no they shouldn't be the same, the threshold for approval should be far LOWER than the threshold for stopping

Expand full comment

In general, they should approve when safety is ensured. Efficacy should be for prescribing doctors to decide based on available evidence (eg trials and papers).

That's how the FDA used to be run until a few decades ago.

Expand full comment

The reason to end the trial is that you want to give paxlovid to all the people in the placebo arm of the trial.

Expand full comment

I mean I get and support that, the point is that if sufficient data has been collected that we can effectively end the trial by giving paxlovid to the placebo wing, we should also approve the drug.

Expand full comment

That could be true in cases where a drug is given at any stage of a slow-developing disease, but I don't see how that's the situation here.

Per the linked Pfizer press release, the trial looked at Paxlovid within either 3 or 5 days of symptom onset. I can't imagine that the study is giving Paxlovid to any meaningful number of people in the placebo arm.

Expand full comment

If you think the side effects will show up in the 1200 already administered within the next few months.

Expand full comment

In which case the correct course of action would be to continue the trial until it's pre-registered endpoint, not stop it early, would it not? That the system allows both the termination of the trial AND the wait until approval is the point, I thought.

Expand full comment

Drug trials are expensive, why continue if you've already got enough data?

Expand full comment

No. Equipoise

Expand full comment

The pre-registered endpoint is something like "3000 patients, *or* sufficient evidence before 3000 patients to trigger an early stop". The early stop conditions are always pre-registered, and always factored into the p value, whether or not they are triggered.

Expand full comment

I think you are misreading him. He says he wants to maximize "expected lives saved", which accounts for any probability-weighted lives lost to side effects. He likely also intends to include lives lost to potential distrust of the medical system, in the unlikely scenario where something goes wrong.

Expand full comment

I agree that was the intention, but we don't know how many probability-weighted lives will be lost to side effects.

The reading of the sentence "If it turns out Paxlovid is terrible, yeah, I’ll look like an idiot - but I care about maximizing expected lives saved more than I care about my reputation." seems to indicate that any expected side-effects will be negligible and the largest risk is to Scott's reputation, whereas the FDA and cautious people (and conspiracy loons) likely rank the risk to Scott's reputation fairly lowly vs. risk of major side-effects.

Expand full comment

I think the confusion is from the word "expected", which is borrowed from the confusingly-named concept of "expected value" in statistics. The connotation for that term is that you weigh all the pros and cons probabilistically. So by using the term, Scott did not mean to connote the costs were negligible.

Expand full comment

I guess his statement does imply that the probabilistic costs of side effects are small relative to the benefits, and I agree.

Expand full comment

"We don't know how many lives will be lost to side effects" is true. A frequentist might say "We don't know how many probability-weighted lives will be lost to side effects," but that is nonsense in a context of Bayesian probability.

If you're confused about whether Yvain is a Bayesian or a frequentist, https://substack.com/profile/12009663-scott-alexander paraphrases Hillel as follows:

Astral Codex Ten

P(A|B) = [P(A)*P(B|A)]/P(B), all the rest is commentary.

Now, go and study.

Expand full comment

If there is a low probability of major side effects, but a high probability of saving your life from COVID, that multiplies out to a net benefit for making Paxlovid legal

Expand full comment
author

Sorry, maybe I was unclear there. I meant that I believe the risk vs. benefit of near certainty of preventing many COVID deaths, vs. small risk of a few cancer deaths, on balance says approve this now.

In addition to that social calculation, there's the *personal* calculation of "nobody ever got fired for going through the usual procedures, but if I say this should be sped up and it's wrong, I will lose lots of reputation".

I'm claiming that I'm doing the right thing by making the socially correct decision regardless of what the personally correct decision is, and asking the FDA to do the same.

Expand full comment

Looking at it further, maybe it was the framing of "X vs Y", where X = expected value, and Y = minor unrelated outcome?

I'm trying to think of a different phrase that would convey the intended message without noise 🤔

Expand full comment

But Scott is not the one deciding if the drug should go into use - he is deciding whether or not to make the post. His personal tradeoff is "should I promote this, even if later it may turn out I was wrong and lives are lost and my reputation is lost due to that" - as the post itself is unlikely to cause the drug to get approved or used much more, just that it gains awareness among his readers.

Expand full comment

I am not yet convinced of your "near certainty of preventing many COVID deaths" statement. This is only true if production is already so ramped up that there will be no post-release supply shortage or if fewer pills will be produced due to the delay.

Expand full comment

No. It’s the people not getting the drug between now and approval who will die in the meantime.

Expand full comment

They would. However, if the argument is to minimize expected deaths you need to account for the whole lifecycle. Under a limited initial supply hypothetical, you could approve now use all available pills. Some lives would be saved now and some people would die later because supply would outstrip demand. Alternatively, you could approve later. In which case more people would die now and fewer later because the pills you didn't give people earlier would be available to meet the excess demand.

Whatever you choose, the expected number of deaths is roughly the same. You can't work out the benefit without accounting for the production/demand dynamics.

Expand full comment

Yeah. Unless the drug has a very short lifespan, it probably doesn't matter if it gets approved now or in two months, as there won't be enough to go around and essentially 100% of the medication will be used either way. So it is really less "will save net lives" and more "it might save more lives now and less later" or vice-versa.

It's unlikely that waiting for approval will actually cost net lives.

Expand full comment

Earlier approval probably leads to faster supply chain scale up. The behavior of vaccine supplies suggests that a month or two faster approval would move forward availability for everyone by a few weeks.

Expand full comment

Merck has been producing their drug for a while now, and they aren't approved. Reality is that they are scaling up to produce the drugs because they fully expect to be approved, and they know they're going to be short even with that lead-up.

Expand full comment

The longer you push back the "we aren't giving it out" phase (for whichever reason, lack of approval or running out of drug) the higher the chance that that phase occurs after the pandemic is over.

Instant approval therefore still has +EV, the magnitude of which depends on how likely you think we are to run out and how soon the pandemic ends

Expand full comment

Don't worry, the pandemic isn't going to end anytime soon.

Expand full comment

A short term exposure to a chemical is not going to raise cancer risk noticebly. There are so many more chronic exposures to more mutagenic chemicals. We've also got tox studies in animals bred to be very sensitive to mutagens that rule out that sort of thing long before first in human studies.

Expand full comment

Probably not, but there definitely are chemicals that do raise cancer risk noticeably with short-term exposure, and not all of them are mutagens.

Expand full comment

Like what?

Expand full comment

I was thinking of asbestos, but there are probably other examples.

Expand full comment

I thought asbestos was pretty safe unless you smoke, and that the hysteria over it was irrational. Even if you smoked, would a short exposure lead to a noticeable increase in cancer?

Expand full comment

asbestos is mostly only dangerous to people who work(ed) in manufacture or installation of asbestos construction materials, because its harm is by physical damage to the lungs when you breath the tiny, razor sharp particles. I.e. if you live in a house full of asbestos insulation, your exposure will be minimal, because it's all inside of walls and generally undisturbed. If you are installing those walls, tearing them down, or on the production line handling lots of raw asbestos, your exposure is significant (but pretty well mitigatable by proper engineering controls and PPE)

Expand full comment

All of that is consistent with my understanding of it as well.

Expand full comment

Many highly radioactive ones can kill with short exposure, but it is via radiation.

I am curious which nonradioactive ones can do this.

Expand full comment

carbon tetrachloride (used to be in fire extinguishers. now mostly reserved for giving lab animals cancer for researchers to try to cure)

Expand full comment

How much needs to be given to cause cancer, and for how long?

Expand full comment

Guess what? We’re not going to know if a given drug increases the risk of miscarriage in humans until after-market trials anyway because pregnant women are usually excluded from most drug trials. But that’s a different problem that Scott might want to write another post about someday.

Expand full comment

Were pregnant women excluded from the Paxlovid trial?

Expand full comment

Yup. From clinicaltrials.gov, exclusion criteria ... Females who are pregnant or breastfeeding

Expand full comment

Shit. Thanks.

Expand full comment

Pregnant women are considered "vulnerable" by HHS Common Rule (a view held by many bio"ethicists") and thus they are bared from a lot of trials even if there is no rational scientific justification for it. Which is very discriminatory and anti-woman!

Some people are trying to change the system because it's so unjust and has led to vaccine hesitancy among pregnant women during the pandemic

https://www.politico.com/news/2021/11/01/covid-vaccine-studies-pregnant-people-518215

Expand full comment

Don't push too far in the other direction. The outcome is going full Australia and having vulnerable people (with anaphylactic reactions etc), who we are told are one of the reasons to push vaccinations as high as possible, being denied mandate exceptions.

Expand full comment

The drug should be offered, with the unknowns and untested parts made clear. It should be up to patients and their doctors, not the FDA, to then decide whether or not to take that risk.

Expand full comment

Ofcourse, there are unknown unknowns too.

Just say that as well.

It could save those 50000 patients.

Expand full comment

Given that ~90% of those deaths will be unvaxxed, 45,000 have already made their choice not to be saved.

Expand full comment

5000 is very high! Even 1 shouldn't die because the FDA is too concerned about its image and too eager to tell us what risk to take.

Tangent : The other 45000 : Come on, ppl make mistakes. They deserve to live too.

Expand full comment

Hersey! Once you disagree with the majority your life is forfeit. That's the only fair way!

/s

Expand full comment

uh, what's your point? Are you implying it's ethically permissible to withhold a life-saving drug from someone because they were too stupid to get vaccinated?

Expand full comment

It was a response to "It could save those 50000 patients.", pointing out that there's already a drug that would save 45,000 of those patients, so on what basis do you postulate that those 45,000 would accept a second drug?

Expand full comment

When the 45,000 refused vaccination, they didn't have COVID. If they're being offered Paxlovid, that means they do have COVID. Having vs not having COVID seems like a pretty good basis on which to change your mind about accepting COVID-related medicine.

Expand full comment

Doesn't cancer typically take years or decades to show up? What percentage of phase III trials actually last long enough to detect changes in cancer risk?

Expand full comment

But the individual that gets covid and wants to take Paxlovid can say "I accept this risk". The FDA literally is making it illegal for folks to make their own risk reward decision.

Expand full comment

Exactly. The FDA has no moral right to do that. These decisions ought to be between patient and their doctor only.

Expand full comment

In much the same way vaccine mandates make it illegal for individuals to make their own risk/reward decisions...

Expand full comment

Not the same way. Because taking the vaccine reduces the risk of your spreading the virus and of taking up a hospital bed with a severe case. It thus affects others.

We need herd immunity. Same reason other vaccines are mandated to attend public school.

I agree though that with a new virus, the details change slightly as new data comes in.

Expand full comment

The vaccine is not 100% protective against infection, nor does it reduce transmission 100% (Both numbers appear to be in the 50%-80% range depending on the vaccine). This at minimum weakens the case for a mandate. As far as taking up hospital beds? You might as well make carelessly breaking your arm illegal. Consider that, in America at least, people are *paying* for their hospital beds, through insurance copays or out of pocket. They have as much a right to a hospital bed as the next person.

Expand full comment

Watch this old video from Milton Friedman's "free to choose" lectures, on this very debate.

Expand full comment

If the vaccine were 100% protective against infection, then there would be basically zero case for a mandate, because people who care could just vaccinate themselves. If the vaccine were 0% protective against infection, then there would be zero case for a mandate, because the vaccine would do nothing to protect others. But when a vaccine is something like 80-90% protective against infection, there is an extremely strong case for a mandate, because the vaccine really does reduce the risk you pose to other people, and there is still a non-negligible risk that the other people are bearing from you even if they protect themselves.

Expand full comment

This assumes that the vaccines are sterilizing. They are not: https://www.npr.org/sections/coronavirus-live-updates/2021/07/30/1022867219/cdc-study-provincetown-delta-vaccinated-breakthrough-mask-guidance

The dropping efficacy and forever boosters makes it more of a sham.

Moreover, for kids, there is no actual proof that it they are effective at reducing severe outcomes since the clinical trial didn't have any severe cases in either arm... they used immunobridging to infer the "level of protection" by correlating it to antibody levels.

Even if they were effective at stopping spread or reducing severity, how is it at all ethical to force someone to take a medical procedure for someone else's benefit? If you are worried about COVID, you can get vaccinated and be protected. Yes, I understand some people can't get vaccinated due to health issues but I think that's a red herring. What percentage of the population is that?

Expand full comment

What do you mean by "sterilizing"? Do you mean 100% effective at preventing all spread?

It seems that yes, it absolutely is ethical to require people who voluntarily enter crowded public spaces to not do so unless they have undergone a medical procedure for the benefit of all the other people present there. With an 80% effective vaccine, each person's vaccination still leaves them some non-negligible concern, and thus makes it quite natural to ask that other people entering crowded spaces with them also do their part to reduce the risk by another 80%.

Expand full comment

That is at most an argument for taxes and subsidies. Not for outright mandates or bans.

Expand full comment

Fine, and then someone does develop cardiac problems in the long term, and then they/their family sue the doctor and the drug company and anyone else their lawyer thinks will stick over "you should have warned us!"

"We did, and you accepted the risk?"

"Well, you should have made sure this was perfectly safe!"

"But you didn't want to wait for the trials and approval process, you wanted it *now*"

"Well, you shouldn't have let us have it anyway, even if we wanted it and said we accepted the risk!"

Expand full comment

It's actually even worse than that. They are saying that *doctors* are too stupid to make the risk/reward decision for their patients. The drug will require a doctor's prescription. Doctors know the patients particular situation and have a lot of experience thinking in terms of risk/benefit trade-offs (unlike FDA stooges who use precautionary principle / are incentized just to minimize risk, and who have shown themselves to suck expected value thinking throughout the pandemic).

Expand full comment

Though off label prescriptions are still legal..

Expand full comment

Not for Paxlovid though, it's not approved by the FDA for anything, so it can't be prescribed off-label. [Ivermectin on the other hand can be.]

Expand full comment

If the FDA approves a wrong drug, there is a clear dead kid that the media can scream about, and the individual guy at the FDA who approved it can be dragged before Congress about why he likes to murder kids.

If the FDA fails to clear 100 drugs that each would save a million lives, there is no clear dead kid, because "I didn't get this medication and died" doesn't have as clear a line, even though we statistically know there must be millions of them.

I get why the FDA operates this way. But it's also a situation that can be fixed. We don't have to stay in this crappy situation forever.

Expand full comment

> you would think someone could either do a cost-benefit analysis (the risk of letting one terrorist through is less than the risk of having all these people get executed after Kabul fell) or take the initiative to come up with some clever solution (airlift them to a military base in the US, let them wait there, and don’t let them out until the not-a-terrorist background check clears).

For Vietnam, they called it Operation New Life and moved 50 thousand people to Guam in a month. I don't think I ever got a satisfactory answer as to why it wasn't possible to get started on something similar a decade ago.

Expand full comment

The US built the Arecibo Telescope in 01963, entered the Vietnam War in 01964, landed on the Moon in 01968, unilaterally "temporarily" reneged on redemptions of dollars in gold in 01971, made their last landing on the Moon in 01972, suspended combat activities in Vietnam in 01973, evacuated 130,000 refugees in Operation New Life in 01975, ended their manned spaceflight program in 02011 (although other countries still flew US astronauts, and in 02020 SpaceX resumed US manned spaceflight), allowed the Arecibo Telescope to collapse in 02020, and withdrew from Afghanistan in 02021.

In short, the US in 02021 is not the same as the US in 01975.

Expand full comment

What’s with the leading 0s there?

Expand full comment

Time traveller mistakes.

Expand full comment

Hmm. A good man to know them is Furrfu. Maybe he has a sports almanac lying around somewhere.

Expand full comment

The US developed a COVID vaccine in 10 months in 2020.

Maybe you should stop cherrypicking.

Expand full comment

Only one - moderna - was entirely a US developed vaccine as far as I can see.

Expand full comment

Some guys in Boston developed a covid vaccine in 4 days in 02020. Then it took them 10 months to be allowed to give it to people because of organizational dysfunction in the organization we're talking about: the US government.

Expand full comment

Yeh…it’s not like that had to test it to make sure it worked and was safe and scale up production. Nope they should have just instantly made up 600 million doses and hoped for the best.

Expand full comment

Human challenge trials could have sped that up dramatically. Under six months seems pretty plausible to me.

Expand full comment

If they had the right challenges. It's not obvious that the vaccines would have seemed effective depending on what kind of challenge they tried. It's also not obvious that a vaccine that is effective against the challenge they tried would be effective against the virus in ecologically real scenarios.

Challenge trials would have been very useful for determining the risk of various real-life exposures, and then what was learned from those might have somewhat sped up the vaccine trials. But I suspect that the real benefits would have been much more in terms of understanding which non-pharmaceutical interventions were valuable and which ones weren't, than in terms of speeding up the vaccine approval.

Expand full comment

We could have made up 10 doses and given them immediately to 10 informed volunteers. After a week, during which time the number of covid cases had increased 4x, if none of the volunteers died, we could have given 100 doses to 100 volunteers. After an additional week, during which time the number of covid cases had increased by an additional factor of 4, we would have known that the immediate lethality of the vaccine was lower than 2%, and we could have given 1000 doses to 1000 volunteers. Within another week, at which point the number of covid cases was about 50 times larger than when the vaccine was first developed and it had spread to most countries in the world, we would have known that the immediate lethality of the vaccine was lower than 0.2%, an order of magnitude better than covid itself, and we could have started giving it to thousands of healthcare workers in Wuhan. Within a few weeks we would have known that the workers who had received the vaccine were getting covid at a much lower rate than the workers who hadn't, so the vaccine was effective and much safer than getting covid.

This would have been late April, 02020. At that point the long-term safety of the vaccine would be unknown; if it caused leukemia three months later in 10% of patients, we wouldn't know yet. But we had excellent first-principles reasoning for believing that the long-term effects of the vaccine are a subset of the long-term effects of the virus itself. And we'd know that vaccine side effects at the two-month mark were mild. So the people of Wuhan would have been taking a risk if they all got vaccinated, but it probably would have been perceived a smaller sacrifice than the ones they were already making.

We could have stopped the pandemic then with the resources we had.

But because of the unearned arrogance and anti-rational strawman reasoning of people like you, as exhibited in your comment, we didn't. Tens of millions of people died, and we probably have a new worldwide endemic deadly disease.

Fuck you.

Expand full comment

"unearned arrogance"

"We could have stopped the pandemic then with the resources we had"

Guess the time travellers from the future still have a pretty good sense of humour.

Expand full comment

Not sure why this is a "win" for the argument that FDA is too slow... we are seeing now that efficacy drops like a rock and now it's boosters til forever.

Expand full comment

Efficacy doesn't seem to drop much for J&J/AZ.

Expand full comment

I saw one news story that said that, and another that said efficacy dropped from like 70% to 3% over 6 months for J&J?? Do you know what the reality is?

Expand full comment

It drops for all the vaccines that we have data on.

Expand full comment

What does this have to do with not approving it sooner?

"Not as beneficial as we hoped" is not at all the same as "had risks we had to dither on."

Expand full comment

"Not as beneficial as we hoped" == "Oops, the approved protocol is wrong, maybe we need three or four or N doses and we have no idea what the risks are there with this new protocol we're making up on the fly"

So now we are literally just winging it. What are the potential side effects? No idea, but according to a commentary article in Science (I think, don't have the citation handy sorry) about Israel rolling out boosters it had the throwaway line "88% of people reported side effects as mild as previous two doses." To me that reads: 12% of people had a worse reaction.

We are in uncharted territory now, worldwide, because we rushed the initial trials...

Expand full comment

Where is that "efficacy drops like a rock" thing coming from? As far as I can tell, the worst we've found is that 90% efficacy against infection has dropped to 60% efficacy against infection after 6-9 months, and 95% efficacy against hospitalization or death has maybe dropped a little bit?

Expand full comment

See https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3949410

"Method: A retrospective cohort study was conducted using Swedish nationwide registries. The cohort comprised 842,974 pairs (N=1,684,958), including individuals vaccinated with 2 doses of ChAdOx1 nCoV-19, mRNA-1273, or BNT162b2, and matched unvaccinated individuals. Cases of symptomatic infection and severe Covid-19 (hospitalization or 30-day mortality after confirmed infection) were collected from 12 January to 4 October 2021.

Findings: Vaccine effectiveness of BNT162b2 against infection waned progressively from 92% (95% CI, 92-93, P<0·001) at day 15-30 to 47% (95% CI, 39-55, P<0·001) at day 121-180, and from day 211 and onwards no effectiveness could be detected (23%; 95% CI, -2-41, P=0·07). ... [Similar story, different details for Moderna/AZ.]"

This is just one study, so who knows, it seems like every study comes up with a different decay rate. How abo0ut the UK's HSA COVID-19 vaccine surveillance report (Week 46? https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1034383/Vaccine-surveillance-report-week-46.pdf

Table 6 on page 23, first two columns, give rates of infection per 100k for vaxx and unvaxx. It shows for age ranges 30+ the efficacy is negative, reaching -100% for ages 40-49 and 50-59. The table shows that they remain effective against hospitalization and death. Taken together, this suggests vaccines are protective of the individual receiving them, but not "the community."

Yes yes, please read pages 14-16, the footnotes on page 24, and the blog post (https://ukhsa.blog.gov.uk/2021/11/02/transparency-and-data-ukhsas-vaccines-report/) and see if you believe their special pleading successfully hand waves away the literal doubling of case rates in the vaccinated population. Moreover, since the purpose of this report is to assess the vaccine performance *in the real world,* you really have to ask yourself if it's ethical to mandate a medical intervention based on this performance in the real world.

Expand full comment

People developed almost 100 different vaccines. That doesn't mean we have 100 functional vaccines.

You are engaging in selection bias. I could have come up with a "vaccine" against COVID in a week, but that wouldn't necessarily mean it would work.

Expand full comment

Manned spaceflight, especially to the moon, was always a vanity thing anyway.

Expand full comment

Most of the Americans left in Afghanistan were people who *wanted* to stay.

Expand full comment

Good post. A historical parallel is the AZT trial for AIDS. In that case, after halting the trial early because of clear signs of treatment success, the FDA gave Compassionate Use exemptions to 4000+ AIDS patients. Let me quote from a summary post of mine (https://willyreads.substack.com/p/a-history-of-the-fda):

"Phase 2 trials which had begun in February 1986 were halted early in September 1986 due to clear signs of treatment success, and AZT was officially submitted to the FDA for approval in December 1986. Eileen Cooper, a rising young star at the FDA, was in charge of reviewing it, and had been reviewing the AZT data for months before the official submission date. Even before the most militant AIDS activists had begun pressuring the FDA, she had been discussing with others on ways to speed and streamline the approval process.

She took two important steps. First, in September 1986 she had released AZT for compassionate use to 4000+ AIDS patients, which likely saved many lives. Second, she sought the support of the FDA's Advisory Committee on Infective Drug Products in a January 1987 meeting, which would symbolically back up the FDA's decision to approve AZT on the basis of a single prematurely ended clinical trial. This would achieve two contradictory goals: the rapid release of a likely effective drug to suffering patients; and satisfy the consumer protection and public health voices that generally urged caution."

So the FDA could and should have issued compassionate use exemptions for this drug, even going off historical precedent, while approval and paperwork checking was going on, as soon as the trial was halted for signs of treatment success.

Expand full comment
founding

You answered my question below. Thanks!

Expand full comment

Ivermectin is not the best choice for that question. We should ask why is fluvoxamine not being given to every high risk patient? There you have efficacy data just as good as for Paxlovid, and a far better safety record.

And there are around 20 other treatments where this question applies.

The six weeks of extra deaths until Paxlovid approval is basically what's been going on since the pandemic started. Almost all pandemic deaths are due to the failure to deploy probably-effective-definitely-safe treatments.

Expand full comment
author

Agreed on fluvoxamine.

Expand full comment

If someone you knew got Covid, would you write them an off-label script for fluvoxamine?

Expand full comment
author

Yes.

Expand full comment

Having first made sure the person was not allergic to fluvoxamine, on medications that would interact adversely with it, or having an existing condition or co-morbidity that would be worsened, such as cardiac disease or a history of same in the family.

There are several medications I can't take, because my doctor went "Let's put you on - oh, no, not with that condition of yours" or "let's try this new one, now there is the very remote chance of this side-effect but it's very rare", and after I took the first couple of doses I started getting the potentially very serious side-effect and had to discontinue sharpish, or else.

For example, with fluvoxamine, there is the risk of QT prolongation which affects the heart rhythm, in sufficiently severe cases causing something lovely called torsade de pointes, "a specific type of abnormal heart rhythm that can lead to sudden cardiac death":

https://en.wikipedia.org/wiki/Torsades_de_pointes

I know I'm susceptible to this, because I already have heart arrhythmia, and developed long QT interval after taking a common anti-histamine (fortunately for me, the cure there was "stop taking that and after a couple of days it will sort itself out").

So, no fluvoxamine for me, even if it works well for high-risk patients (and I'm the type who *is* a high-risk patient if I *do* get Covid).

This is what drives me crazy about such demands for "Give everyone X!" because this is the kind of "read the small print" need that people calling for X don't take into account.

Expand full comment

No need to be driven crazy. That's medicine. I'm sure we'll discover plenty of problems with Paxlovid. All I said is that we have a better safety record for Fluvoxamine.

Expand full comment

I don't think there is the same level of evidence for fluvoxamine as for paxlovid.

Paxlovid was developed specifically for SARS-CoV2 with (I think) a reasonably well understood mechanism of action. Their phase 2/3 study shows an effect on mortality as well as on the composite endpoint of hospitalisation or mortality.

Fluvoxamine is repurposed; no clear mechanism of action; was trialled initially for a pretty random reason (some person thought why not https://online.flippingbook.com/view/329200553/9/). The main study shows an effect on a composite endpoint of "observation in A&E for 6 hours"/hospitalisation/death. Almost all the effect is on the least objective component of this composite endpoint, the observation for 6 hours in A&E. There is a good reason to think that participants, and possibly treating physicians were not completely blinded to allocations given the very large differences in adherence between the SSRI and placebo arms. So I would worry the effect is being driven mostly by behaviour.

Expand full comment

There was a trending effect for deaths. While not statistically significant, it was the same relative risk ratio as for hospitalizations (0.68), which argues against the hospitalization reduction being driven by unblinded subjective factors.

https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltext

> "There were 17 deaths in the fluvoxamine group and 25 deaths in the placebo group in the primary intention-to-treat analysis (odds ratio [OR] 0·68, 95% CI: 0·36–1·27)"

Expand full comment

I'm not saying there is no evidence for benefit, all I'm saying is from a Bayesian perspective the probability that SSRIs actually are useful is less (lower a priori probability, higher likelihood that the results can be explained by chance+bias)

Expand full comment

SSRIs as a class show no effect on Covid outcomes (https://www.medrxiv.org/content/10.1101/2021.10.25.21265218v1.full.pdf). The beneficial effects are specific to fluvoxamine, and they aren't that great if you consider death to be an important outcome.

Expand full comment

Observational data from hospital records could be horribly confounded in all sorts of way and in either direction. "adjusted logistic regression model was run to account for age category, gender, and race" doesn't cut the mustard I'm afraid...

Expand full comment

Isn't the "per protocol" group pretty impressive? (1 death in the treatment, 12 in control). Is that a usual thing, to separately track a subset of patients who reported high adherence to the prescribed dosage?

Naively it looks like a neat trick to me, if many patients aren't really taking the medication enough (because it's not administered in a controlled environment) then we're not really testing its effects and we should expect middling results, so let's focus on the patients who actually took the damn pills? I guess this biases for conscientiousness, but is that a cause for concern? I haven't really seen this "per protocol" thing before, genuinely curious what to think of it.

Expand full comment

Isn't this the missing story here? Good to see lots of action on Paxlovid and related efforts, but where's the show on fluvoxamine? That stuff was already looking good a full year ago (https://jamanetwork.com/journals/jama/fullarticle/2773108).

Why was its study not properly funded during the year? Don't governments have money to throw at a seriously promising treatment?

Then last month the TOGETHER trial came out with clearly positive results, positive enough that it was stopped early for fricken *efficacy*.... and what do we hear? Crickets! Where are the FDA and the EMA? Where are their equivalents in Third World countries that would have the most to gain from it?

I honestly don't understand.

Expand full comment

And meanwhile the monkey show goes on and on with Ivermectin, long enough to get Scott writing one of his longest posts ever! At least we got the fluke pun for it...

Expand full comment

Go read the TOGETHER study again. Specifically, Table 3, line 8. No effect on death rates. Even the primary endpoint, hospitalization, was less than a factor of two - and you still die. Time to move on.

Expand full comment

The Moderna vaccine was developed in March 02020, a few days after the genome was published. China was offering a covid vaccine to government officials and students who had to travel abroad in July 02020, a more traditional vaccine, I think. The Moderna vaccine was approved in the US in November 02020.

Not just almost all pandemic deaths but almost the entire pandemic are due to the failure to deploy possibly-effective-probably-safe treatments.

Expand full comment

Yep, the Chinese vaccine is a bog-standard killed-virus vaccine. It turns out it's about as effective as the flu shot against Covid Classic: not that great, but a lot better than nothing.

The big advantage of a killed-virus vaccine is that it's standard and easy to produce. MRNA vaccines use brand new machines which are super hard to make and use. Even if Moderna and Pfizer had been rubber-stamp-approved in March 2020, we wouldn't have been able to produce much of them for a long while. As it was, Pfizer was struggling to produce enough of its vaccine for the clinical trials. Maybe they would've gotten more if they'd actually been rubber-stamped in March and scaled up right then as fast as possible... but I wouldn't assume at all.

Expand full comment

Aren't the "brand new machines which are super hard to make and use" just thermocyclers? I guess I don't actually know how the mRNA vaccines are made. Aren't they just RNA? Whose quantity you can double with PCR once a minute? I'd think the problems you'd have with that would be more a question of purity, contamination, and mutation load, rather than production capacity. But what do I know? I've never so much as plated a bacterial culture.

Expand full comment

It's the microfluidic machines that stick the RNA inside lipid nanoparticles that's the bottleneck. This is needed to protect the mRNA from the RNAses we produce to make life harder for viruses. From what I've heard, they haven't managed to scale it up to industrial-scale equipment and are stuck running a bunch of bench-scale processes in parallel.

Expand full comment

Thanks!

Expand full comment

> The big advantage of a killed-virus vaccine is that it's standard and easy to produce.

Are you saying we could have had a standard vaccine in large volumes much sooner than we got with the mRNA rollout?

Expand full comment

Yes. Absolutely. It wouldn't have been so good, but it would've been a lot better than nothing. It would've spoiled antibody tests to see if people have ever had COVID in the past (people who've gotten Sinovac return positive on antibody tests; people who've gotten mRNA/J&J return negative because they've only encountered the one spike protein), but that's much less important.

Expand full comment

So I'm really confused now, because I had thought that the main benefit of the mRNA vaccines is that they could be formulated much faster than traditional vaccines.

Expand full comment

I think they can be REformulated faster in response to variant changes.

Expand full comment

Yes, once you have the production capacity. In March 2020, we didn't have the production capacity, so mRNA took a while.

Now, the problem is that the FDA has forbidden any changes without prohibitive tests. Pfizer had a Delta-specific vaccine back in July, but the FDA blocked it.

Expand full comment

I'm pretty sure that this is backwards. It's definitely standard and easy to produce a killed-virus vaccine, but it's not faster. It takes nearly a year to produce enough doses of the flu vaccine for people in the Northern Hemisphere, at the relatively low uptake rate that it usually gets, even though we've been investing in capacity for decades. Whereas the mRNA vaccines are being produced in larger quantities already, despite using new factories.

Expand full comment

Evan above seems to disagree, so I'm still not clear on the real answer. What is the main production bottleneck for traditional vaccines?

Expand full comment

I probably am stating this more confidently than I should be. I'd be interested to hear what Evan says.

This brochure seems to suggest that growing the vaccine in eggs isn't actually as slow as I thought, but there's a lot of processing that has to happen after that. And it also sounds like the entire process is run once in a given year, with the number of eggs involved selected for the projected demand, rather than running continuously. I don't know if there's something about one method rather than the other that makes continuous manufacture harder or easier.

https://www.gskvaccination.com/content/dam/assets/516007R1_FluVaccineManufacturingProcess.pdf

Expand full comment
founding

In the 1957 influenza pandemic, we went from "this strain looks like it might be scarier than usual" to large-scale vaccination in the US and UK in six months. Not at the numerical scale of 2020 Covid vaccine production, but I don't see why the process couldn't be parallelized on whatever scale is desired.

The mRNA vaccines are faster in that you can get your *first* dose faster, like maybe Dr. McCoy in the third act fast, whereas killed-virus takes I think two or three months to produce anything useful and attenuated-virus longer than that. If you've also got a large-scale encapsulated-lipid production line standing idle, then maybe the whole process is faster.

But of course we didn't have that in early 2020. We also didn't have any confidence in what was then a very new and untested technology. It would have been prudent (though fortunately unnecessary) to have someone working on a classic known-mediocre vaccine as a backup to the various clever new technologies we bet everything on.

Expand full comment

There's actually a whole lot of other vaccine candidates that had been worked on other than the ones that got approved. We just don't hear about them much. I think some of them were abandoned in part due to the others coming out sooner or better than hoped. It looks like there was one French company and one Japanese company working on inactivated virus vaccines, in addition to five or six Chinese companies, a couple Indian ones, and others by the governments of Iran, Turkey, Kazakhstan, and maybe more.

https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html

Expand full comment

"There you have efficacy data just as good as for Paxlovid". The TOGETHER study (fluvoxamine) did find a 99.8% chance of superiority over placebo for their primary endpoint of hospitalization, but the degree of superiority was no better than a factor of two (CI95% [0.52- 0.88]). For the secondary endpoint of death, the death rates were indistinguishable (2% vs 3%, p=0.24). In the Paxlovid study, the treatment arm had no deaths while the placebo arm had 10 deaths (~500 people per arm). If you care about dying, I don't think fluvoxamine is nearly as good as Paxlovid. Indeed, fluvoxamine appears to be worthless.

Expand full comment

"Despite two doses of Comirnaty, I was forced to take a regimen of Paxlovid".

Seriously, the vaccine and the drug are great, but do they have to make it sound like we are living in a negative utopia?

Expand full comment

The largely unanimous and bipartisan mocking of the abject terribleness of the name "Comirnaty" has been one the bright points of this whole pandemic experience for me. Don't take this away from me.

Expand full comment

What's so funny about that name?

Expand full comment

It sounds like you're trying to say "Community" with a mouth full of walnuts.

Expand full comment

I see "co-morbidity" which isn't something I want.

Expand full comment
founding

If effectiveness and safety were the reasons the FDA stopped the trial, then it makes no sense not to approve it. It would be interesting to know other examples of stopping a trial of drugs for the same positive reasons and when those drugs were approved.

Expand full comment

The same thing happened with Merck's drug, Molnupivir.

The stoppage was mentioned in an October 1st press release:

"At the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration (FDA), recruitment into the study is being stopped early due to these positive results"

https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/

The EUA legislation gives the FDA a lot of authority - they could EUA right now if they wanted. However, they won't EUA until the committee meeting, which they have scheduled for Nov 30th. https://www.fda.gov/advisory-committees/advisory-committee-calendar/november-30-2021-antimicrobial-drugs-advisory-committee-meeting-announcement-11302021-11302021

So earliest EUA is Dec 1st, 9 weeks after the press release, and 7 weeks after Merck submitted their EUA application.

Pfizer submitted their application Nov 16th. So the median Metaculus prediction of Jan 1st is in line with the Merck example, sadly (I say sadly because the death rate has been pretty steady at ~1,200 per day and case rates are going up again).

Expand full comment

Will rushing even save a single life?

I'm skeptical. Unless the drug has an insanely short lifespan, there's a good chance there won't be enough to go around for months no matter what we do.

Expand full comment

I'm skeptical manufacturing is the bottleneck especially at a big company like Pfizer and give the statements from the company. See a couple tweets I did on this here:

https://twitter.com/moreisdifferent/status/1461689013627150353

Expand full comment

Those numbers are all assuming there are no issues with scaling up production.

And we are at 100k cases/day, ish. 180,000 pills by the end of the year is nowhere near what is needed. And would only represent an order of magnitude increase in production.

Merck has been producing pills assuming their drug would work and be approved; they didn't wait for approval to produce their pills, they started doing it months ago at risk (i.e. if the trials failed, they would have piles of useless pills).

Expand full comment

Note also that molnupiravir is not a new drug; it has been kicking around for several years. It was originally developed to fight influenza. So they've had more time to work with it - it entered phase I trials against influenza in 2019, before the pandemic even began. They've had a lot more time to work out the process for mass manufacturing.

Expand full comment

All good points.

Pfizer has requested that the initial EUA be considered for high-risk patients only so hopefully the FDA/CDC/doctors will all work to ensure the limited supply is targeted accordingly.

Please check out my post from this morning - it addresses some of the other objections that have come up in this comments section:

https://moreisdifferent.substack.com/p/the-fda-has-blood-on-their-hands

Expand full comment

By the way, I don't know _anything_ about biochemistry, but the new Merck RNA-garbling pill molnupiravir sounds a tiny bit ... terrifying. From StatNews:

Will it affect a patient’s DNA?

This is really a question only for Merck’s molnupiravir, since it works by sneaking subtly corrupted parts into the coronavirus’s RNA sequence.

Once the virus has mutated too much, it can’t work — mission accomplished. But there’s a theoretical chance that molnupiravir could also influence normal human DNA when it replicates, too. If mutations happen during that process, it could spell real trouble.

Merck did some tests during molnupiravir’s development to check this possibility out. In two different types of animal studies using higher and longer doses than are given to humans, Merck’s scientists didn’t see any increased risk of unwanted mutations. ...

But UNC’s Swanstrom isn’t completely convinced that the tests Merck did were sensitive enough. In August, he and his colleagues published a paper in the Journal of Infectious Diseases showing that a key metabolite of molnupiravir could mutate DNA in animal cells.

Given these results, Swanstrom said he would be particularly interested in seeing a long-term study of people who took molnupiravir to continue to monitor this potential effect over the next 10 or 20 years.

“This thing is going to go into thousands of people. And are we just going to ignore the fact that there’s this potential risk?” he said. “The risk could be zero. It could be no worse than going to get a dental X-ray — or it could do something more. But unless we find out, you know, we’re going to learn this lesson the hard way, way later than we should.”

Expand full comment

Merck's pill is said to be only 50% effective at keeping newly infected covid patients out of the hospital, compared to 85%-89% for Pfizer's new pill. So, if you can only take one, you'd want Pfizer's.

But, if they operate wholly independently, it would be nice to have Merck's pill available to double the efficacy of Pfizer's pill alone.

We need more tests to figure out if that is true.

We also need studies of how these pills work on the vaccinated. I believe the initial efficacy studies are only of the unvaccinated in order to get a sufficient sample size fast enough.

Expand full comment

It's a case of duelling experts once again.

Looking this up, there's an infectious diseases expert warning about use:

https://newsinfo.inquirer.net/1518775/be-careful-in-using-covid-drug-molnupiravir-infectious-disease-expert-warns

"Please be careful with molnupiravir. Long-term use has mutagenic potential. It is currently only for high risk populations with CONFIRMED mild/moderate COVID infection under compassionate use and only for 5 days. Beyond that narrow application, the risk-benefit ratio of this drug remains UNCERTAIN and can be potentially harmful. If you have severe COVID, it doesn't really work and other meds need to be used. NEVER take any meds without proper medical consultation. Stay safe!"

So maybe not quite the same thing as Paxlovid, and certainly it sounds as if caution in using it is warranted.

Expand full comment

And of course Merck's press release is going to downplay any concerns and claim that it's safe, wonderful, and should be on sale right now. I'm not calling them liars, I'm just saying that after pouring millions into developing this, they want to see a return on that as fast as possible.

There's also a political angle, so I don't know if this guy was being honest or just another anti-Trump official:

https://en.wikipedia.org/wiki/Molnupiravir

"Alleged safety concern

In May 2020, Rick Bright, director of the US Biomedical Advanced Research and Development Authority (BARDA), filed a whistleblower complaint, alleging that the Trump administration ignored his early warnings about the COVID-19 pandemic, pressured him to inappropriately fast-track unproven drugs, and illegally retaliated against him by removing him from his role as head of BARDA in April 2020.

Among these complaints, Bright objected to providing additional federal funding to Ridgeback Biotherapeutics to further develop molnupiravir into a treatment for COVID-19. He argued that although the drug had shown potential against coronaviruses including SARS-CoV-2, it had already received substantial government support."

Expand full comment

Much of the cost benefit analysis is predicated on Pfizer being able to unleash a flood of pills. If production takes time to ramp up and demand exceeds supply at any point during the initial post-approval period, then the cost (in lives) of the delay would be near zero.

I don't know, and have not been able to find any information on, what Pfizer's production curve looks like. I'd love any sources on that folks could share.

Expand full comment

It would be near zero. In theory they could auction of the pills to the most efficient user.

Expand full comment

Probably the most efficient user is not in a position to participate in an auction because they are intubated and heavily sedated.

Expand full comment

It must be given in the first 5 days of symptoms so you've missed your window if intubated. That said, your point still stands. The person in a position to spend the most at auction is likely not the one who it will be most likely to help.

Expand full comment

Oh, I didn't realize that. Thank you. In that case an auction would probably be fine.

Expand full comment

And my point wasn't so much that a literal auction would be the best way to go about things.

But in general, if a good is available earlier (and can be stored) that has (economic) advantages over later availability, even if the total amount is the same.

Expand full comment

Huh, An auction seems bad to me. Rich people will buy it and save it, instead of the drug going to infected people.

Expand full comment

If they've already got the factories churning under the assumption that approval will be granted, does it really matter in the long run? Like, those pills will be made tomorrow, they'll find patients to take them, they'll save lives. Whether they save lives in a week or in 2022 doesn't seem relevant from a policy perspective.

And if drug availability is the bottleneck, it makes sense from an optics perspective to build up enough of a stockpile to not have stories about rationing and bare shelves as soon as approval is granted.

Expand full comment

I believe Scott's argument is essentially: it matters to people who die in the interim.

Expand full comment

Yeah, but Scott cares about (average predicted) number of lives saved. If 10 people get saved tomorrow, but then three months down the line 10 people die due to supply issues, how is that any better than waiting for approval and saving the latter 10?

Expand full comment

The 10 people saved tomorrow had no good alternative treatment options while the 10 people 3 months down the line will have other options besides this one because (following the lead set by this one) other new treatments are likely to have been approved. And we'll know more about how well this one works - like we might work out (based on the early use) that half-doses work well and thereby double the supply.

Expand full comment

Very true, and those 10 people will have lived another 3 months!

Expand full comment

One word I don't see mentioned anywhere is "manufacturing." It's one thing to make enough drug for a clinical trial, it's another to make millions of commercial doses reliably. FDA approval requires inspection of and confidence in these commercial-scale manufacturing processes.

Expand full comment

I was thinking this too. Although manufacturing shouldn’t preclude approval.

Expand full comment

To expand on this more: the clinical trials only show that *that one particular batch* was safe and efficacious (the FDA thinks this, since they agreed to terminate the trial early). Pfizer must then show that the commercial batches will be identical in every relevant way to the clinical trial batches, so that they will have the same safety and efficacy. What are the relevant ways? Pfizer must decide that, and justify their decisions to the FDA with supporting evidence.

Scaling up chemical manufacturing is not trivial (a regular contender for Understatement of the Year). E.g. heating and stirring work differently in different sized reactors. Heat transfer in and out of your reactor works through surface area, but heat produced/consumed by the reaction depends on volume. If your stirrer design isn't right for the viscosity of the solution, you might get hotspots and so on.

Ideally, the FDA expects you to understand the chemistry so thoroughly that you know everything that can possibly go wrong, and design your commercial process so that none of these things can possibly happen. The commercial batches will therefore be identical *by design* to the clinical trial batches, and you have to prove this with science. Of course in practice you don't have to have collected all the evidence before you can start selling batches, but you must have your plan in place with a solid scientific justification for every decision you made along the way. It also helps to have made a statistically valid number of commercial batches to show that your beautiful process works as designed (how many batches is that? you tell me, and justify your decision).

Pfizer/Merck will have thrown everything at this problem alongside the clinical trials, as they can afford to do this, so their regulatory submissions will be pretty good. However they still might have to store the new batches for a few months to demonstrate that they have a comparable shelf-life to the old batches, and FDA might wait to see this data etc.

Note that this really only applies to new chemical entities; people have been manufacturing fluvoxamine for years and its probably well understood by now. Not always true though; we saw a worst-case situation recently with the ranitidine withdrawal: a medicine that some reasonably healthy people take every day of their lives was shown to be contaminated with small amounts of a nasty carcinogen. If Pfizer happened to have some gaps in their understanding for the Paxlovid process, the FDA might go easy on them as dying of Covid now is worse than a slightly increased risk of cancer in the future, but it takes time to review all of these risks and make a justified decision.

Expand full comment

Yeah, unless the medication has an insanely short shelf life, it's likely that they'll be short on it regardless for months anyway as they ramp up production, and having bad batches of pills could kill use of the drug even if it does work.

Same reason why we didn't just mass innoculate people with experimental vaccines last year - a lot wouldn't work, so it would undermine confidence in the ones that did.

Expand full comment

To also expand on this: There's a real-life example as well. The EMA (the European counterpart of the FDA) is still reviewing the Russian Sputnik vaccine, and says the current delays are due to their inspections of the manufacturing facilities. Some EU countries, e.g. Slovakia, did not wait for EMA approval, and bought Sputnik early on. Then they found that what they received wasn't really what they expected (a claim the Russians hotly disputed).

https://www.nytimes.com/2021/04/08/world/europe/slovakia-coronavirus-russia-vaccine-sputnik.html

Expand full comment

Thanks for this. I see the commentary from Scott and others about how "why doesn't the FDA just approve it already and save tons of lives", and all I can think is, "You should know better; it's a lot more complicated than that."

Scott makes a lot of assumptions he doesn't even realize he's making when he assumes it's as easy as just churning out a bunch of this stuff in record time. I manage the clinical portfolio for a startup oncology-related pharma company, and I'm amazed when I see the speed at which some of these companies are pushing COIVD-related drugs.

Every step in this process takes a lot more time than people realize, and there are a lot more steps than people realize. It's not just the regulations that makes this take time. It gives me a lot less confidence when I see Scott talking about something within my field of expertise and making wildly inaccurate assumptions, that when he's speaking about something outside my field of expertise he's not making the same wild assumptions.

Expand full comment

What are the assumptions, then? You are the expert. If you don't tell us, we won't know.

Expand full comment

Scott's thesis appears to be: Paxlovid efficacy has been demonstrated to be 90%, with no strong safety concerns; the FDA's delay in approving it until Q1 next year will cost tens of thousands of lives; if they approved it sooner that would save tens of thousands of lives.

But I don't expect them to roll out enough doses to save even a majority of those patients if the approval comes tomorrow. I'm sure FDA approval is in the critical path, but it's not the only thing keeping patients from getting the drug.

If we can blame the FDA on the people who die while they're in the midst of their admittedly expedited review of this drug, does that mean we also get to blame the person working in the manufacturing facility for not making more of it? Or the analysts confirming the CoA? How about the project manager who accidentally got key priorities mixed up? Are they responsible for thousands of deaths, too? Should the medical writer be ashamed of taking Thanksgiving off instead of turning around the FDA meeting request documentation a little early? What about the people working in regulatory, legal, biostats, etc.?

There are a lot more people behind the approval, manufacturing, and launch of any treatment than just the FDA. A pharmaceutical company knows when they have good data and are likely to get an approval. They know the government is already guaranteeing they'll buy doses. Say we 'fix' the FDA approval issue and get an approval a few weeks early. Who do we go after next? Who gets the death toll blamed on them for not doing their job fast enough?

I'm only asking because I have a dog in this fight. I work in cancer, I believe what I'm doing is important, and I believe my company's approach has the potential to change the way we treat the disease eventually. I and everyone I work with are working hard to accelerate the process, but I'm also taking a vacation this year to spend time with my family. If we're successful and we produce a few drugs that dramatically change the nature of cancer treatment, I just want to know when they'll come blaming us for not getting the work done sooner.

Sorry, I realize that comes across a little hostile. I'm just watching all this COVID-related research happen at lightning speed compared to 'normal' clinical development like what we're doing in oncology. And then the public reaction seems to be, "Sure, but why didn't you do it faster?"

Kind of like this: https://www.youtube.com/watch?v=PdFB7q89_3U

Expand full comment

And then after pouring all the money and effort into making an effective vaccine in record time, you still have 10%(?) of the population screaming about how they won't take it because the Bill Gates microchip will let the Jewish Space Lasers control my mind and fascism and freedom and my DNA is going to get all evil and stop calling me stupid and I want a hug and to own the libs. It can get you down, if you let it. I like the German Health Minister's take: "Probably, by the end of this winter, as is sometimes cynically said, pretty much everyone in Germany will be vaccinated, recovered or dead." It's a calming thought. (OK. I'm better now.)

Expand full comment

My admittedly not that well informed impression of this is that governmental regulatory agencies are uniquely bad at their job compared to everything else in this pipeline. I suspect this is due to misaligned incentives. The researches and project managers have an interest in making working medication, and having it be there fast. I have the impression that institutions like the FDA do not. Their sole incentive currently seems to be not having people suffer side effects from medication ever.

This seems like something that might be fixed if broader groups of people became conscious of the trade-offs involved with this epsilon risk tolerance approach. Then the FDA could be held accountable for the consequences of their policies, shifting their incentives. Hence, complaining loudly about the FDA seems like a possibly useful thing to do.

I do not see any similar systematic ways to improve the work of research labs and pharmaceutical companies. Their incentives seem about as well-aligned as we can make them, at least in this capacity. Hence, I have no reason to complain about them. If we wanted them to work better and quicker, the obvious solution would be to pay them more. I don't think that would work with the FDA or other FDA-esque organisations.

Expand full comment

All I can speak to is my own personal experience. The division of the FDA I've been working with does not fit the description you just gave. Indeed, we met with other PhD scientists who gave valid commentary and suggestions, people who had reviewed our submission thoroughly enough to comment on nuances we wanted to highlight/discuss.

I'm not saying the complaints you have aren't valid, I'm just saying I don't recognize the FDA you're describing from my interactions with them. We met with a group of people who were interested and engaged with the process, even if the interaction was not a normal collaborative discussion.

Expand full comment

It's also worth noting that the 90% efficacy rate is based on an absolutely tiny data set. I don't actually expect it to be 90% effective.

Expand full comment

Look up Gell-Mann amnesia. You seem to not have it.

Expand full comment

Is there a Gell-Mann paranoia? This past year I feel like I've contracted that, where I see sustained bad reporting in my field that I just assume it's all bunk and stop believing anyone about anything. In early 2020 I thought it was a great time to be an immunologist...

Expand full comment

Amen. Whenever I read about X my response is either "I'm not going care about X, so, whatever" or "OK, now I have to spend quality time on PubMed to see if what I'm reading has any points of contact with reality." The upside is that I've learned a boatload by reading all those papers.

Expand full comment

During the pandemic, I have learned that a lot of people can convince themselves of untrue hypotheses by going to the primary literature when they don't have a solid foundation in the subject matter. For example, biologist PhDs who don't know immunology convinced themselves that early reports demonstrated antibodies weren't long-lived for COVID-19 because they didn't understand normal effector B-cell contraction, and related concepts.

PubMed is certainly useful, but a quick search of the primary literature isn't a replacement for a PhD anymore than a quick search of WebMD is a replacement for an MD. Which is a little depressing when I want to go spend some quality time on PubMed confirming whether X is real or not.

Expand full comment

I mean, you should. Reporting is absolute garbage.

It's just as bad about everything.

Look at the Rittenhouse case, and how many articles are completely at odds with the reality of what happened.

They're the kind of errors that would be made by people who didn't even look at the videos.

Expand full comment

The people at the FDA have to read and analyze these applications which can run tens or even hundreds of thousands of pages. That takes time even if you have adequate resources, which the FDA does not. That’s how we avoid another thalidomide, which would be the worst possible outcome. They seem to have an all hands on deck approach here, but it does take time, and it is necessary to dot all the I’s and cross all the T’s.

Perhaps I am being too solicitous, but that’s my take on this situation.

Expand full comment

We are accepting a virtually guaranteed cost of tens of thousands of lives in order to hedge against a very remote risk of a repeat of an event that cost thousands of lives (which you describe as the worst possible outcome). That isn't being solicitous. That is being irresponsible.

Expand full comment

Perhaps, but such an outcome would destroy the credibility of an agency that we really need, as if they haven’t done enough damage themselves recently.

Expand full comment

Saving lives is far more important than the FDA's reputation, not that their reputation is still salvagable.

Expand full comment

Unfortunately FDA's reputation is the metric people use when deciding whether to trust any new FDA-approved vaccine/drug. Every lost point of FDA's reputation could potentially mean another million of lives lost in the next pandemic.

Expand full comment

This is such a bizarre claim to make with no evidence. It’s pretty clear from this pandemic, that people will distrust drugs for reasons that are impossible to predict or control. So why are you advocating doing the wrong thing in order to hedge reputation?

It reputation strategy doesn’t even make sense either. You are trading off the guaranteed and very severe reputation damage if withholding life saving medicine from dying people. With the unlikely and less severe reputation damage if doing the wrong thing and getting unlucky. It’s poor logic all around.

Expand full comment

An "FDA takes too long to approve medication" reputation damage is very different from an "FDA rushed an untested drug and it backfired" kind of damage.

As far as I'm aware, The main reason that the not-crazy (i.e. the ones that could possibly be reached by reasonable means) vaccine-hesitant people cite is "the vaccine had not been tested long enough", and the more often FDA-approved drugs display unforseen side effects, the more reasonable that line of reasoning would look (note that I'm not saying that it is in fact reasonable in the case of Covid vaccines).

Expand full comment

The FDA does no research into what affects its reputation and how its reputation affects lives saved. They are, as Josh Barro writes, amateurs when it comes to psychology. https://twitter.com/jbarro/status/1463149716775047172

Expand full comment

Institutional reputation is more valuable.

We're seeing the costs of institutional reputation lost every day here and it's very, very real.

I get that you think they're just dumb people, but we're talking about net lives lost and the only reason we're talking about the cost/benefit of rushing this drug to market is because of institutional reputation lost that's stopping 50% of the country from taking the proper preventative measure.

Expand full comment

Are people really failing to get vaccinated because the FDA too quickly approved things in the past? Or do they have no idea how to target the psychology of the public, thus the drop in vaccinations after the "pause" of the Johnson & Johnson vaccine?

Expand full comment

Dr. Marty Mackary says this : "As a Johns Hopkins scientist who has conducted more than 100 clinical studies and reviewed thousands more from the scientific community at large, I can assure you that the agency’s review can be done within 24 to 48 hours without cutting any corners." https://thedispatch.com/p/fda-career-staff-are-delaying-the

also keep in mind we are not talking about full approval here and the requirements for what needs to be in an EUA application is all stuff the FDA invented during the pandemic (the EUA legislation, https://www.law.cornell.edu/uscode/text/21/360bbb-3) only requires that "known and potential benefits of the product... outweigh the known and potential risks of the product"

Expand full comment

You know what a 3-legged race is, right? Two people run as a unit, with the left leg of the person on the right tied to the right leg of the person on the left. The unit does not run nearly as fast or as well as a single two-legged runner. Well, organizations like the FDA are like a 5000-legged race. All these people are tied together in various ways so that the whole mass takes the shape of a 4-legged beast, eachleg made out of 100's of people tied together leg-to-leg, head-to-toe, or human-centipede style. Then the big fucker tries to walk a few blocks. You will not be surprised to hear that it does not walk fast or well.

Expand full comment

Pfizer issued a press release on 11/9/2020 of the unblinded results of their vaccine. (As StatNews made clear that day, Pfizer had curiously shut down processing of their results from late October until the day after the election, likely delaying release of the positive news until after election day. Perhaps not coincidentally, leading Democrats like Biden and Harris and Democratic-affiliated scientists had been spreading Fear, Uncertainty and Doubt all fall about the "Trump Vaccine.")

The FDA's issuance of an EUA came 32 days after the press release on 12/11/20.

The UK started giving Pfizer jabs on 12/8/20 and the US started giving Pfizer shots on 12/14/20.

The initial rollout over Christmas was pretty lackadaisical in the US outside of a few states like West Virginia and the Dakotas and didn't really get into gear nationwide until later January.

Expand full comment

For anyone interested in the vaccine-timing conspiracy theories, it's worth noting that Pfizer were waiting for the FDA to approve their require to look at more samples. The fact that they stopped processing samples while waiting for the FDA to approve the request is a standard practice, and any clinical trial which is suddenly faced with the prospect of receiving much more data than expected would do the same.

Expand full comment

By shutting down lab processing of their vaccine clinical trials from late October 2020 until the day after Election Day so that they wouldn't know how many cases had been recorded, Pfizer managed to blow through not only its first planned checkpoint (32), but also its second (62), which it was asking the FDA to accept, and its third (92).

Expand full comment

It seems to me the same people who complain that they are being idiots for not doing something are the same folks who will complain when they do something and it blows up in their face. Tons of 20/20 hindsight, etc.

Expand full comment
author

I hereby commit to not complain if the FDA approves a drug too quickly and it blows up and causes problems, unless they were really stupid about it and any moron should have been able to figure out it was bad in the same amount of time the FDA took.

Expand full comment

Anyone can look like a moron in 20/20 hindsight.

Expand full comment

That's what we have prediction markets for.

Expand full comment

Agree. But some people who look like morons in hindsight could have gotten better marks from the judgment of history if they had been smarter or more honest or just tried harder. Others assessed the facts they had well and acted with great energy and smarts, but can look dumb in retrospect if you don't bear in mind that there was crucial info they just did not have access to.

Expand full comment

Why does it seem to you that way? Do you have any evidence for it? In my experience an awful lot of FDA critics are people like me who just want the FDA to get the hell out of the way or be entirely abolished. Whether people use a drug should be up to those people, their doctors and their pharmacists. If we make FDA approval voluntary, let anyone sell drugs with a "not approved yet" sticker then by definition it's not the FDA's fault when drugs people use don't work. Nobody is asking the FDA to *guarantee safety* of these drugs, we're simply asking them to let the drugs be used REGARDLESS of whether the FDA is satisfied with their safety.

Expand full comment

Bad actors will ruthlessly exploit and maim America’s legions of morons. You don’t care about them but most people do.

Expand full comment

I care more about all the people dead because the FDA made it illegal to give them lifesaving drugs.

Expand full comment

Why do you care more about them than the million that will die as the result of deadly snake oil?

Expand full comment

1. I haven't seen convincing evidence that the FDA actually does save many lives. 2. Deaths that can be avoided (by not using a product) weigh less in my mind than those that can't. The latter group of people who will die unless the FDA gets out of the way have no option but to damn the FDA.

Expand full comment

So in world where the data says chemo will be hell and offer a 40% survival rate and snake oil will be amazing and 100% effective the average person will say - as compelling as the lie is I side with the truth. That’s how you think the world works? People never fall for comforting lies vs an unpleasant truth?

That’s really what you think?

I don’t mean to be disrespectful. I promise to respect your response.

Expand full comment

Hundreds of thousands of people died because of your (and others') fetish for calling Americans morons. HUNDREDS OF THOUSANDS. DEAD.

Expand full comment

"Nobody is asking the FDA to *guarantee safety* of these drugs, we're simply asking them to let the drugs be used REGARDLESS of whether the FDA is satisfied with their safety."

Which is how things used to be before approval bodies were set up, and people were being marketed a range of substances from the useless to the actively deadly.

If you're happy to go back to "you have a condition, this treatment might not work or it might kill you or maybe, very seldom, it can help" then good luck to you. I would rather know "if you take this drug in combination with that medication you are already on, it's going to make your liver explode, so don't do that!"

Expand full comment

How about both?

Expand full comment

> I came away from the pushback convinced that nobody would ever believe the FDA was dragging its feet until I could make them read about it in flagro delicti - write a post saying the FDA is dragging its feet now, on this thing that you and I currently realize is obviously good.

Should be "in flagrante delicto" (https://en.wikipedia.org/wiki/In_flagrante_delicto). "In flagro delicti" means "in the whip of the crime".

Expand full comment

Out of curiosity, does "stop the trial" mean "stop collecting data and give the drug to everyone in the control group" or does it mean "stop collecting data and stop giving the drug to anyone".

if it means the latter, then I fail to see how "it would be unethical to continue not giving to to the control group" makes sense, given that the potential control isn't getting it either way.

Expand full comment
author

I assume it means the first one, on the same reasoning as you.

Expand full comment

I'm actually not so sure. It is true that sometimes they give the drug to people in the control group for ethical reasons, but in the case of the vaccine trials it took several months before the participants were unblinded, and only after some protests were raised (I heard a participant on NPR for instance demanding to be unblinded and allowed to get the vaccine in spring this year).

Expand full comment

Haven't read the pre-registration, but given the nature of the drug, I assume that the participants were recruited as they were contracting Covid. So as soon as the trial had been stopped, there were no new participants in either the control or the treatment group and hence no one to give or not give the drug to. (I'm also assuming that the people previously entered into the control group are out of the treatment window at that point anyway).

Had the trial continued to recruit participants, putting each new participant into the control group would mean performing an action that would knowingly increase that person's risk of death or severe illness (as opposed to putting them into the treatment group). But if you're not recruiting any new participants, you're not knowingly increasing any particular person's risk of death. The vast majority of people that would contact Covid in the interim would likely not have been participants in the trial anyway, so none of them can say that their risk was significantly increased by stopping the trial.

Expand full comment

They already had contracted Covid:

"About the Phase 2/3 EPIC-HR Study Interim Analysis

The primary analysis of the interim data set evaluated data from 1219 adults who were enrolled by September 29, 2021. At the time of the decision to stop recruiting patients, enrollment was at 70% of the 3,000 planned patients from clinical trial sites across North and South America, Europe, Africa, and Asia, with 45% of patients located in the United States. Enrolled individuals had a laboratory-confirmed diagnosis of SARS-CoV-2 infection within a five-day period with mild to moderate symptoms and were required to have at least one characteristic or underlying medical condition associated with an increased risk of developing severe illness from COVID-19. Each patient was randomized (1:1) to receive PAXLOVID™ or placebo orally every 12 hours for five days."

Expand full comment

70% of 3000 is 2100. I wonder what happened with the 2100-1219=881 remaining patients.

Expand full comment

It completely has to do with equipoise and informed consent. Equipoise means that, with the available evidence, you're not certain which treatment is better. Once you've done a pre-specified interim analysis that shows that one treatment arm is better (like happened with paxlovid), you no longer have equipoise. The second issue is informed consent. Before enrolling in a trial, a patient has to be told the risks and benefits of entering the trial. At this point, to enroll a patient in a paxlovid v. control trial honestly, a doctor would have to say something along the lines of, "You'll be randomized to either a good treatment or a bad treatment."

To be clear, I am also frustrated by the delay between the trial being stopped for efficacy and the FDA approving a medicine I wish I could prescribe. I'm not sure what the reasons for delay are, and I would love to hear the perspective of an insider because I would really just be speculating as to why it takes so long. But I think a lot of the discourse I am seeing in this thread are looking at the pros and cons of early approval are narrowly focussed on COVID lives saved or lost rather than the integrity of a system of investigation and regulation that has allowed for BILLIONS of life years of meaningful life extension.

It seems to me with the limited information that I have that the FDA could speed things up without significantly increasing the chances of a catastrophic miss where many people receive an unsafe medicine. I'm really curious what insiders at the FDA would candidly say about unreasonable delays. However, the downside to a catastrophic miss (no matter how unavoidable) is that it further undermines the trust in this system (which is already pretty low). The FDA's reputation matters ENORMOUSLY to many questions outside of COVID and far into the future. How much needless death and suffering have we seen because of poor vaccine uptake? And how much of that poor uptake was due to a lack of trust in regulatory institutions?

Expand full comment

I would hope it means ' give the drug to everyone, but keep gathering data and compare them to the thousands of controls front different Covid trial that we already have on file.'

No reason to stop gathering data, even if your controls are no longer perfect you can notice big things if they happen.

Expand full comment

I'm uneasy with the elimination of a control groups by ending a trial early and giving the drug to the control group. They did this with the vaccine, too. Okay, it's hard to say no to the obvious humanitarian argument. Still, at the point when the control group is eliminated, all we've learned is that the drug seems safe and effective (for some p-value) in the short-term; we don't know anything about the long-term.

Expand full comment

I think you underestimate the power of very, very large observational "post-market" follow-up studies which the FDA often requires. We know that serious side-effects from vaccines are almost always rare (< 1 / 100,000) so you need very large sample sizes to detect them in any case. I'm not aware of any previous vaccine having long term side effects, nor of any scientific reason for believing that would be possible. Do you know of any examples?

Expand full comment

> We know that serious side-effects from *modern vaccines* are almost always rare

These are new mRNA vaccines. What quality of them makes you feel the long-term effects of them are comparable to the modern vaccines in this historical way?

Expand full comment

Because mRNA goes away after a short period of time.

Vaccine injury will pretty much always appear very rapidly simply because the vaccine doesn't stick around at all, so there's nothing there to cause further injury.

Expand full comment

> Because mRNA goes away after a short period of time.

You can prove this with evidence and the data we have today after the fact?

So the thousands of cases of myocarditis in teen boys (now included in warning label of these vaccines) is occurring because the mRNA is not there anymore?

Expand full comment

mRNA is unstable and disappears very quickly.

mRNA vaccine tech has been in development for decades.. in 2013 there was a mRNA vaccine for rabies that was tested in humans. There's also been mRNA vaccines for cytomegalovirus and Zika tested in humans.

it's also conceptually not much different than viral vector vaccines (using DNA) which have been developed for Ebola previously.

there's no biologically plausible mechanism which could lead to long term effects and it seems to me we understand this area of biology pretty darn well at this point

Expand full comment

"there's no biologically plausible mechanism which could lead to long term effects"

You mean with or without repeated boosters and/or other mRNA vaccines? I understand there is concern about mRNA crossing the blood brain barrier and ending up in the brain and other areas of the body where it is undesirable, resulting in cells in those organs being attacked by the immune system. In fact my understanding is that we KNOW this happens, we just think the amount is very low, but we can't be sure.

Expand full comment

I highly doubt that because 1. The liquid nanoparticles which contain the mRNA are probably too large to cross BBB and I'm guessing they would have designed them so this is the case. 2. They are designed to be engulfed by dendritic cells that then migrate to lymph nodes. In theory, dendritic cells are the only cells that the liquid nanoparticles and actually get inside. You can read about this stuff here: https://www.nature.com/articles/s41577-021-00526-x https://en.wikipedia.org/wiki/Dendritic_cell

Expand full comment

There's a lot of probably in there and not a lot of proof and actual data. Oh wait, the data and proof is in myocarditis and number of vaccine related deaths we have today.

Expand full comment
Jan 4, 2022·edited Jan 4, 2022

> mRNA is unstable and disappears very quickly.

You can't surely show any rigorous data to show this because this was the shortcut that was taken to expedite this product to market.

The thousands of cases of myocarditis in teen boys (now included in warning label of these vaccines) is occurring *exactly* because we were wrong about the mRNA disappearing quickly. It (or at least the spikes) circulate in the body and make their way to the heart.

Probably also the reason for the growing rate of miscarriages.

Expand full comment

the spikes are not supposed to detach from the cell wall but some do float in the blood stream. If you look at the rates of the severe side effects and deaths they are very low - myocarditis is about 1 / 200,000 for males ~20-30 and the other severe side effects like clotting are like 2-3 in a million. Chances of death from the vaccine are at most 1 in a million and your risk of death goes way down if you don't have a history of allergic reactions to vaccines. COVID also causes myocarditis, clotting, and death at much higher rates (10x in the case of myocardits, maybe ~100x in the case of clotting and ~1000x or more for death depending on your age). Yes the vaccine has risks but the benefit to risk ratio for the vaccine is pretty clear.

Expand full comment
Jan 5, 2022·edited Jan 5, 2022

> COVID also causes myocarditis

Where is your evidence of this claim in the target group, of males 20-30?

>myocarditis is about 1 / 200,000 for males

myocarditis of 1 / 200,000 is a lot higher and more unacceptable than the 1 / 10,000,000 side-effect we were originally told about. and myocarditis is not an unserious thing. one estimate I've heard says about 13% of those cases are super serious life-shortening cases, the rest aren't a walk in the park either.

Now look at that 1 / 200,000 number and compare it to chances of a bad outcome for someone in that age group with covid. It isn't looking so clear-cut for the vaccine anymore.

>Yes the vaccine has risks but the benefit to risk ratio for the vaccine is pretty clear.

Yes, the vaccine's real risks are becoming more transparent and coming forward as different from what was promised or estimated from the initial launch. The benefit to risk ratio is hardly pretty clear at all.

Expand full comment

There's 0 shot we have had real-life practical data for the "tech being in development for decades". in 2013 the mRNA vaccine for rabies failed miserably. Why have all our past mRNA tests failed?

Expand full comment

> I'm not aware of any previous vaccine having long term side effects

https://www.ncbi.nlm.nih.gov/books/NBK223724/

"It is well established, for example, that the oral polio vaccine can on rare occasion cause paralytic polio, that some influenza vaccines have been associated with a risk of Guillain-Barré syndrome"

Expand full comment

Many vaccines can cause Guillain-Barré syndrome in about 1-in-a-million. My understanding is that Guillain-Barré is rapid-onset, so it shows up quickly once you have a lot of people taking the vaccine.

The polio vaccine is a really interesting case because some polio vaccines are a weakened but live virus. That virus can mutate over time and spread from person to person. So in that case I see the potential for longer-term risks. But that's a special case and the mechanisms there don't apply to CV-19 vaccines.

https://www.npr.org/2019/11/16/780068006/how-the-oral-polio-vaccine-can-cause-polio

There is a longer-term risk for Molnupiravir to cause evolution of a more dangerous virus that might interest you. I've read about it and it seems a very low risk (especially considering CV-19 seems to be at an evolutionary dead end) but it is there. See:

https://www.science.org/content/article/prominent-virologist-warns-covid-19-pill-could-unleash-dangerous-mutants-others-see-little-cause-alarm

https://www.science.org/content/blog-post/molnupiravir-mutations

Expand full comment

I just addressed the specific question as to whether there are long-term side-effects from previous vaccines. Guillain-Barré syndrome can last years, which I consider long-term. Perhaps you meant side-effects that only show up long-term, but that wasn't clear from context. Recent reports of myocarditis might qualify.

Expand full comment

Yeah, I meant side effects that show only after long term (by long term I mean > 2 months).

It seems any rare side effect (that shows up either in short term or long term) that is less than ~1 in 100,000 is unlikely to be detected in an RCT regardless how long you wait. (The CV-19 RCTs have at most 20,000 people in active arm and they were unusually large).

Expand full comment

The other side of this concern is that people are assuming the positive side of the results are statistically valid. Oncology trials are often stopped early for ethical reasons, similar to the rationale in this study. The result is that trials stopped early are much more likely to overstate the treatment effect.

This is selection bias at work. I'm sure there are also trials closed down early due to lack of efficacy, but those are usually closed down because even if the remainder of the patients responded to treatment it wouldn't have been enough to generate a sufficiently positive result to continue.

I'm not saying there's not efficacy for this drug. I'm saying it's unwise to assume it's as high as 90% because it was stopped early.

Expand full comment

^ that's a good point. My guess/hope is data safety monitoring boards that monitor trial results in real-time try to correct for in their statistical analysis but how good a job they do, I don't know.

I want to mention again that observational studies, like case-control studies, can provide more info on the efficacy at a later date.

Expand full comment

Yes, and there will be additional study data. I'm simply cautioning that a statement about saving 50,000 lives based on an assumed efficacy of 90% should be taken with a huge grain of salt, given that there's a known mechanism by which these results are likely to be overstated. We can say, "Yeah, that's good enough efficacy to be approved" based off these data, without excoriating the FDA as negligent-murderers for not approving it sooner because they weren't super credulous about the data as it stands today.

Expand full comment

Even if it's only 20% effective, many lives will be lost because of the delay.

<rant> I do think the FDA is doing something similar to murder, by the way. I don't think a person does something equivalent to murder when they spend money on their own children or a vacation rather than saving lives by spending that money on GIveWell's top charities. So I recognize the act-omission distinction has some relevance when judging behavior.

However, I do think the FDA does do something equivalent to murder when people die because they delay approval, and they know full well people are dying because of their delay. That's because it is in their mandate to "protect the public health" and when there's a nasty virus going around that means approving life-saving treatments in a timely way to save lives. It's like if during wartime someone entrusted by the public to defend the country decided to just sit around and let the enemy attack and kill innocent victims - that is akin to murder to me.

Now they may have some cockamamy excuse for murdering those people, like "we wanted to maintain our process / rigor / reputation / prestige" but I have always found those arguments to be quite a stretch.. Also to me some of those arguments are like the dude who refuses to save a drowning child because he will ruin his suit. The FDA already has an insane amount of rigor and prestige, and lessening that rigor slightly here for an EUA (which is the rational thing to do) will not damage it much. And again, we aren't talking about a full approval!

I am almost certain that at least thousands of courses of Paxlovid pills have been manufactured. (Pfizer is producing 180,000 course of treatment by the end of the year. https://www.reuters.com/business/healthcare-pharmaceuticals/us-govt-buy-10-mln-courses-pfizers-covid-19-pill-529-bln-2021-11-18/)

The fact is, FDA officials could sign a document today releasing drugs to at-risk patients under expanded access or EUA and save lives starting the next day but they don't. </rant>

Expand full comment

I understand the sentiment, and might have agreed with you once. I think it's harder for the decision makers than it is for armchair decision makers.

For example, you can easily just say, "It's good, we're only asking for an EUA. If you don't like it, just rescind it!" But how many fast-tracked drugs that didn't go on to show any efficacy got rescinded, despite the rules explicitly requiring this? Indeed, back in the SSC days Scott complained about exactly this problem. So maybe we save a few thousand lives today, but then we can't ever get rid of this thing for the same reasons you can't stop the fast-tracked drugs once they're out there and newly-entrenched interests won't let go of them.

Maybe we realize after the fact that it was oversold, and maybe that there are serious safety concerns that we'd have discovered if we'd just gone with the already-accelerated route instead. It's tough to go down in history that way. If it's your name that will be put into textbooks as an example of why we don't compromise our principles in the face of an emergency, maybe it gives you a little pause.

I don't think the FDA is the best possible route for instilling public confidence in medical practices. But I do think there's a history of questionable 'medical' practices for which we can demonstrate that treatment was worse than the disease. (A disease it often didn't really treat!) In comparison to the historical structure that produced the kind of treatments that led to e.g. the Romanovs trusting a crazy spiritualist over doctors who were literally killing their child, I think we could do a lot worse than the FDA. Of course, we can do better, and we should absolutely work toward a better system, but I don't agree with calling the work the FDA is doing murder, or tantamount thereto.

So if your argument is, "The FDA should be improved/reformed so we get more true positives and are better able to weed out/reverse decisions for false positives," I'm with you. If instead your argument is that, "We should jettison the FDA because in this specific instance we think we can save a lot of lives in the short term," then call me skeptical.

But I admit I have a bias against one-time emergency measures that require us to jettison principled stances. They don't have a great retrospective track record. If the principles are wrong, let's reevaluate them and reform the system on the merits. If we don't like our principles because we don't like the outcome this one time, but otherwise we agree they're sound, maybe we don't really have principles to begin with.

Expand full comment

I am definitely saying "The FDA should be improved/reformed so we get more true positives and are better able to weed out/reverse decisions for false positives." I'm 100% not saying anything like the FDA should be abolished.

I'm sorry if I haven't been clear on the view I'm actually trying to advocate. I'm saying the threshold for letting people take a new drug/treatment should dynamically adjust based on the situation, which is what economists like Alex Tabarrok have been advocating for for some time. So, for a pandemic, when 1,200 are dying a day, lower the threshold.. you'll get more false positives (approvals for stuff that doesn't actually work) but fewer false negatives (lack of approval for stuff that works).

Same thing for life-threatening illnesses where there is no treatment - the FDA should shift the threshold lower. On the flip side, for drugs where there is already a good treatment or for non-important stuff like treating acne or male pattern balding, they should shift the threshold higher.

The FDA actually does this to some extent, but it's not formalized very well and there's little transparency into the decision making process. The EUA legislation was actually crafted precisely with the goal of lowering the threshold during emergencies by throwing out all requirements other than a basic requirement that "the expected benefits outweigh specific harms"... but perversely the FDA is trying to keep the threshold the same as in non-emergency times which is incredibly irrational and (I believe) unethical.

Expand full comment

"Like everyone else, I hate the fact that pharmaceutical companies are the only people with enough resources to run high-quality studies, and that this controls what drugs we end up using."

For COVID the single most influential clinical trial in terms of drugs we are (and are not) using is RECOVERY - not a pharma led trial

Expand full comment

One thing that I agree with the ivermectin conspiracy theorists on is it's really odd and bad that the NIH never funded a large scale trial on ivermectin early on.

Expand full comment

It seems entirely reasonable to wonder why it ever had to be 'amateur hour' with ivermectin testing. Well, 'wonder' is not stating it genuinely. It seems entirely reasonable to observe that there was an obvious motive not to trial ivermectin with the same zeal as Paxlovid.

Expand full comment

Why didn't the pharmacy companies do these types of studies for Ivermectin?

Expand full comment

Ivermectin is already approved. And probably out of its patent protection time.

Expand full comment

Yes but I mean they all vilified Ivermectin for its ineffectiveness, without ever doing large-scale studies like they did for these "newer" drugs. And of course all you would have left to study it are smaller studies because the engine that drives our studies here appears to be those same pharmacy companies. Is that not a catch-22?

Expand full comment

Did the pharma companies do the reviling? I thought they were rather quiet about it.

Expand full comment

Merck came out with a public opinion piece on their website against it.

Expand full comment
author

They did eventually do large-scale trials: RECOVERY and TOGETHER. They didn't work.

The reason Paxlovid started with a large trial and ivermectin started with small ones is that Paxlovid is a new medication that requires pharma support to get through the FDA process, and ivermectin was an old one that was getting boosted to attention by the efforts of random individual doctors. Once the random individuals boosted it to the system's attention, people ran the big trials and they failed.

Expand full comment

What are you referring to exactly? Ivermectin was never part of the RECOVERY trial. It is included in the PRINCIPLE trial, but no results have been published yet.

Expand full comment

A search through the RECOVERY trial reveals it did not include Ivermectin.

Expand full comment

Ron DeSantis and the government of the State of Florida could have directed the hospitals and medical schools to conduct a study. They didn't.

Expand full comment

While some of those studies were truly useless, small studies and those with weaker methodological rigor are very useful in helping determine where to follow up and focus large rigorous trials. In the case of Ivermectin, the follow-up trials did not prove out the large effects that were hoped for.

Paxlovid didn't have small weak studies because it was purpose built to fight Covid.

Expand full comment

> the follow-up trials did not prove out the large effects that were hoped for.

When I hear about this, I want to investigate the design of the studies and any conflict of interests. I desire to learn how to analyze study design more and whether something was off. Any suggestions on ways for me to apply this methodology to studies like the ivermectin large-scale follow up studies?

Expand full comment

I don't know what you mean by "apply this methodology," but I thought Scott did a really good job with his writeup a few posts back.

Expand full comment

I mean to say I am looking for ways to increase my ability to read studies and also analyze for design flaws and issues with the studies, and wondering what the best way to approach that might be. Maybe a book or other knowledge base.

Expand full comment

This is a great question and I don't have a fantastic answer for you. Going from zero to synthesizing a heterogeneous set of studies in some scientific domain is a long road. I have a PhD in statistics, have worked in infectious diseases for over a decade and been a statistician on several clinical trials. Yet there are still areas that I don't feel comfortable with my own ability to critique the literature (e.g. All the stuff around furin cleavage sites etc.).

Looking at my bookshelf, the closest thing to helpful would probably be "Fundimentals of Clinical Trials." Very few equations, and I don't think the material requires much in the way of prerequisites.

https://www.amazon.com/Fundamentals-Clinical-Trials-Lawrence-Friedman/dp/3319185381/ref=sr_1_1?keywords=fundamentals+of+clinical+trials&qid=1637643243&sr=8-1

Expand full comment

You could check out the Studying Studies series by Dr. Peter Attia. I haven't read all of it but he seems very knowledgeable on the topic.

https://www.google.com/url?q=https://peterattiamd.com/ns001/&sa=U&ved=2ahUKEwjmrvfa7a30AhUESjABHdIHCiAQFnoECAAQAg&usg=AOvVaw1DHGjfcmk7X9nisZ19l5FS

Expand full comment

> I know I’m not going to convince many ivermectin supporters. So consider this: ivermectin is FDA approved. It’s approved against parasitic worms, but that’s fine: once a drug is approved for anything, any doctor can (more or less) use it for whatever they want. Doctors can absolutely prescribe ivermectin right now if they want, and many of them (like Pierre Kory) have. The ones who don’t prescribe it are avoiding it because they think it doesn’t work, not because the FDA is trying to prevent them.

False. You seem to be a bit removed from the situations hundreds if not thousands of patients have faced. Doctors even. Doctors getting placed on leave, fired, discouraged from prescribing Ivermectin. Even Pharmacists are banding together on /r/pharmacy saying they won't fill the prescriptions. Heck, Dr. Paul Mark, Front line critical care doctor, suing Sentara hospital in Virginia because Board of Directors wouldn't let him prescribe it.

Expand full comment

>The medical regulatory system has made prescribing ivermectin legal and easy.

The medical regulatory system has failed us. It has started to play doctor, and prevented doctors from practicing medicine and prescribing drugs like Ivermectin that their education trained them for.

Expand full comment

"The medical regulatory system has failed us. It has started to play doctor". That's actually pretty funny.

Expand full comment

Suppose ivermectin does feck-all as regards Covid. Your doctor shrugs and prescribes it anyway when you demand it, because it won't kill you.

Best case: it does nothing. You have wasted time and money taking a pill that won't do anything for you. You might as well have been taking sugar tablets.

Worst case: it does nothing. You are convinced you are now shielded from Covid, so you don't get vaccinated, you don't take precautions, and you contract Covid. And maybe you are a high-risk patient, so now it turns severe and you have to be hospitalised.

Expand full comment

I came to the comments section specifically to make this same point essentially (but perhaps a bit more cordially). To Scott, I definitely recommend doing a bit of research on the current ivermectin off-label prescription situation. While in *some* jurisdictions and hospitals you can prescribe it and patients can receive it, there are *many* situations around the US where doctors are not allowed to prescribe it and when it is prescribed it is not uncommon for people to find it very difficult to actually acquire because pharmacists are refusing to fill.

I know that what you have described here is how the US medical system is *supposed* to work. Off-label prescriptions are a core part of the US's medical establishment. However, in the case of ivermectin specifically the system has become somewhat dysfunctional in some areas (not all).

If off-label prescriptions weren't being bureaucratically/administratively blocked then I would generally be OK with the current situation. If some doctors think it works and they prescribe it and people can get it and others don't think it works that is OK. In the long run the doctors with a track record of treatment success will come out the winners, and there will be a survivor bias in the future towards patients who utilize those doctors.

The problem is that when you make a drug hard to acquire, the marketplace of medicines no longer functions properly. It is like a prediction market where there is some external downward pressure placed on anyone who bets on one of the outcomes (e.g., higher fees for people betting on one side). This can skew the final results and potentially cause an incorrect prediction. Market economics only function when they are free from constraints, which is not the case with ivermectic (regardless of whether it works).

Expand full comment

Hospital administration is not the FDA (and not even a part of the medical regulatory system). I know it's a small consolation to people trying and failing to get/prescribe Ivermectin, but FDA is not the one to blame here.

Expand full comment

While I agree that the FDA isn't *directly* to blame for the ivermectin restrictions, I don't think they are helping the situation with things like their infamous "you are not a horse" tweet.

That being said, the statement made by Scott is not entirely true:

> Doctors can absolutely prescribe ivermectin right now if they want, and many of them (like Pierre Kory) have. The ones who don’t prescribe it are avoiding it because they think it doesn’t work, not because the FDA is trying to prevent them.

While the last bit is true (the FDA isn't the agency blocking people from off-label prescriptions), the rest of the statement is not true for many doctors and patients in the nation. There are doctors who *cannot* prescribe ivermectin if they think it is the best treatment for their patient and there are doctors who avoid prescribing it not because they think it is ineffective but because they fear for their employment/career prospects.

There are definitely some doctors who think ivermectin doesn't work, and I fully support them *not* prescribing it to patients. What I don't support is patients being unable to switch doctors to one who will prescribe/administer it, or patients who do get a prescription being denied the ability to fill that prescription by pharmacists (who shouldn't be deciding which medications are appropriate for a given patient).

Expand full comment

Yeah, I guess the proper way to say it would be "The ones who don’t prescribe it are avoiding it because they OR THEIR BOSSES think it doesn’t work"

Expand full comment

I think that is a plausible scenario.

It is also possible that there are perverse incentives that cause people to not prescribe it even if it might work. I think such behavior is much less likely to be seen in doctors and more likely to be seen in administrators.

Politics are incredibly ugly/dirty, and I *assume* that we can agree that at this juncture the line between medicine and politics (particularly around COVID-19) is thoroughly blurred. One can *imagine* some administrators making decisions based primarily on politics, and those decisions then getting pushed down onto the doctors/pharmacists.

Expand full comment

Curious why people don’t feel the same sense of urgency about lives lost, say to lack of medical insurance, in this country?

Expand full comment

Well for starters, because lack of medical insurance won't kill me or anyone I care about, whereas covid might.

Expand full comment
author

Causing harm seems worse than failing to prevent harm. If the government banned me from feeding my child, and sent cops to my house to make sure I didn't sneak him any food, this seems worse than the fact that there are children starving because they can't afford food - or at least it's easier to complain about.

Expand full comment

"Causing harm seems worse than failing to prevent harm". I'm sure the FDA thinks that way, too.

Expand full comment

Given the topic is them causing harm in an effort to not fail to prevent harm, what makes you say that?

Expand full comment

Presumably, a medication prescribed and causing harm is worse than it not being prescribed and failing to prevent harm. Though Scott seems to be more concerned with people having options, so it's possible to draw a distinction there.

Expand full comment

Everyone seems to be talking as if this is a new miracle cure - take it and you won't contract Covid, or if you have it, it will clear it right up.

I'm not seeing that, and the EMA is also not approving paxlovid on the bare trial results alone, although they want it as fast as possible:

https://www.ema.europa.eu/en/news/ema-starts-review-paxlovid-treating-patients-covid-19

"Paxlovid is an oral antiviral medicine that reduces the ability of SARS-CoV-2 (the virus that causes COVID-19) to multiply in the body. The active substance PF-07321332 blocks the activity of an enzyme needed by the virus to multiply. Paxlovid also contains a low dose of ritonavir (a protease inhibitor), which slows the breakdown of PF-07321332, enabling it to remain longer in the body at levels that affect the virus. The medicine is expected to reduce the need for hospitalisation in patients with COVID-19."

And that's the summation there: "the medicine is expected to reduce the need for hospitalisation". Not "cure you completely". Not "prevent you ever getting it". Not even "nobody will need to go to hospital". REDUCE the need.

Let's all calm down a little, okay?

Expand full comment

Because we know how to fix "lives lost for lack of Paxlovid" without causing any risk to anyone who doesn't choose to take the drug. We don't know how to fix "lives lost for lack of medical insurance" without tearing apart our current healthcare system and risking everyone who might have to interact with it ever.

Expand full comment

Because we're aware of things like the Oregon Experiment? Having medical insurance makes people use more health care but doesn't make people notably healthier. If you think lack of medical insurance causes lives lost that is a claim that needs some support, it can't simply be assumed. https://www.nejm.org/doi/full/10.1056/nejmsa1212321

Expand full comment

If by healthier, you mean specifically "prevalence or diagnosis of hypertension or high cholesterol levels [or] ... prevalence of measured glycated hemoglobin levels of 6.5% or higher", then sure. On the other hand, if you look at depression levels, or catastrophic expenditures, then it helped with those. Of course, the study specifically looked at able-bodied adults under 65, so it's unclear to what degree the results generalize.

Expand full comment

Depression levels & catastrophic expenditures are a far cry from "lives lost".

Expand full comment

Uh, not always that far, unfortunately.

Expand full comment

Ok, but the context here was regarding having and using health insurance, not COVID and lockdowns.

Expand full comment

That is true. However, the study only looks at outcomes like hypertension and depression, and only in a relatively healthy demographic. It may very well be the case that universal insurance doesn't save lives, but this study doesn't really show that.

Expand full comment

The RAND health insurance experiment looked at lots of outcomes. And the Oregon experiment was not "only in a relatively healthy demographic":

https://www.overcomingbias.com/?s=Oregon

"The RAND experiment was mainly on random people, though it over-sampled from people with the lowest 20% of income. The Oregon experiment, in contrast, is on very sick and poor folks. For example, “healthy days per month” above refers to to how people answered a survey question on the number of days in the last 30 that poor physical or mental health impaired their usual activity. On average people in this study were impaired for ten days per month! 28% of them have asthma, 30% high blood pressure, and 56% depression."

Expand full comment

Okay fair enough, they may not have been particularly healthy. I guess I don't really want to get into a debate about whether health insurance helps, I just wanted to push back on the idea that a study that doesn't measure mortality can be used as evidence that health insurance doesn't affect mortality. There may be other studies that show that, but that specific link to that specific study isn't it.

Expand full comment

> Having medical insurance makes people use more health care but doesn't make people notably healthier.

Sure, if you entirely discount mental health and other quality of life measures, like solvency.

Expand full comment

How many doctors are sitting around twiddling their thumbs doing nothing?

One of the things a lot of people fundamentally don't understand is that the biggest limitation on the medical system is the availability of medical resources.

Medicare for all doesn't actually increase the number of doctors - and doctors are very busy as-is.

Expand full comment

Because health insurance is not health care and health care is not health. The RAND health experiment & the more recent Oregon RCT showed an increase in health insurance doesn't really seem to increase health.

https://www.overcomingbias.com/2007/05/rand_health_ins.html

https://www.overcomingbias.com/2011/07/the-oregon-health-insurance-experiment.html

Expand full comment

People on here love to reference these studies. But a simple google search will show that both studies had significant limitations, conclusions are not as simple and clear-cut as claimed, and a quite different interpretation is possible.

Expand full comment

That sounds like a lot of hand-waving, in a "google it for yourself, I'm not here to do your research" form. People love to reference those studies because as RCTs they provide the best causal evidence on the effect of health insurance on health.

Expand full comment

If you google "problems with this study I don't like" you'll surely find it.

But beware the man of one study https://slatestarcodex.com/2014/12/12/beware-the-man-of-one-study/

Expand full comment

Why didn't the pharmacy companies do these types of studies for Ivermectin?

Expand full comment

Large high quality studies were done. The results were... less than awesome.

Expand full comment

Same answer as in the prior thread.

Expand full comment

It could also be FDA is playing the long game. The cost of a false positive for a drug approval is enormous as it erodes trust. So maximizing saved lives on a long enough of a time horizon could actually be withholding a drug that's virtually certainly good.

It could also be that it's bureaucracy in its worst. I don't know why they can't sit around the clock and do whatever they would do in six weeks in one.

Expand full comment
Comment deleted
Expand full comment

Those all look like examples of short term thinking targeted at immediate/short term results to me, not playing the long game.

Expand full comment

No one in government is rewarded for actually playing the long game because nobody is evaluated for making correct predictions over the long term.

Expand full comment

The "it could erode trust" thing is certainly a theory that some people have but it doesn't seem like a very GOOD theory. Me, I would have a lot more trust in the FDA if they were truthful about what they know, did reasonable cost-benefit analyses and behaved sensibly in a timely fashion with urgency proportional to the needs of the situation. An FDA that pretends to be slow-but-infallible to "maintain trust" (while constantly making dumb errors of over-caution) isn't one worth trusting and has in fact already lost the trust of many of us.

Expand full comment

The vast majority of people the FDA is trusted with overseing would hardly go at such lengths in their reasoning. For them it's more like "oh I remember that one drug the FDA approved and it caused cancer, maybe I should refrain from taking that emergency-approved vaccine for now". I mean, there already *are* millions of people that think like that.

Expand full comment

I really admire someone who can think like this and write like this. Another great post!

Expand full comment

Forgive me if this is a silly question, the first time I'd heard anything about Pavloxid was today. Which leads me to my question: why isn't this ALL OVER the news? I guess I would understand the FDA stuff flying under the radar, but there's not even a single headline letting anybody know that "Wildly Effective Covid Drug Has Been Discovered And Is For Real This Time"? Is it because of the chloroquine stuff? Is it because the Kyle Rittenhouse verdict just came out? Is it a coincidence?

I asked some friends who are progressive leaning peers at my fancy schmancy small liberal arts college, and they also had never heard of it.

Expand full comment

I saw headlines several weeks (or a month?) ago about the early trail results of this drug. But the reality is that "good news" is rarely as newsworthy as "bad news" or "politicized news".

Expand full comment

The press _is_ publicizing it, although the best articles I've read have been in Stat News.

I'm sure the media doesn't want people not getting vaccinated because they figure they'll just take the new miracle pills after they get sick.

Expand full comment

I don't think it is some grand "media" conspiracy. There have been a bunch of treatment advances and they all seem to get a similarish level of reporting. This has gotten much more than most. However, it is hard for people (including reporters) to grasp the massive quantitative and qualitative difference between a 50% reduction in hospitalization and a 90% reduction. Both are often just reported as "scientists find an effective treatment!"

Expand full comment

I'm not familiar with this particular decision but when I was involved with a study that stopped early it was the DSMB that made the ethical decision. Are you sure it was the FDA that stopped the trial? If not, there is no ethical paradox. I for one wouldn't want the FDA to cede regulatory/ethical decisions to a heterogeneous collection of study boards of mixed quality.

Expand full comment

"I honestly believe they’re operating on Fast Mode, well aware that the entire country is watching them and yelling at them to move faster."

Government bureaucrat time is not like human time. If i ran the zoo, I would have soldiers surround the FDA during the middle of the day, and I would tell them: "Free pizza and Coca Cola, but no one leaves until you have this nailed down."

Expand full comment

And what if "nailing it down" involves "we have to wait a year to make sure there isn't a nasty surprise lurking when this goes from clinical trials into the population at large, and someone who takes it today won't suddenly keel over dead six months from now"?

Some things you can rush, other things you have to wait and see because there isn't any quicker, better way of finding out.

Expand full comment

Their clothing will rot and fall off them and they will be sick of cold pizza for breakfast.

Expand full comment

The trial absolutely should have continued. It's already going to be hard enough to get some people to take the drug.

Expand full comment

Soo...if this drug works this way - does anyone predict that they will roll back the vaxports and other casual removal of various rights for not getting vaccinated? Covid was never more than maybe 5 or 10 times more deadly than the flu. If this makes it 10 times less deadly then covid is just another version of the flu essentially. Will we have some two tiered society and somehow in 20 years you'll still be barred from certain jobs if you're not vaccinated against Covid?

In a country and world where tobacco and alcohol are legal and fast food is subsidised through things as varied as cash handouts to big ag, tax breaks or zero tax for companies, and profit friendly ultra low minimum wage levels below the poverty line... In a nation where we know that the people in charge really really care about us, but just can't bring themselves to ban tobacco when they are in the mood to start banning things and firing people 'for our protection'. Will they remove all the mandates and stop firing people for not getting a vaccine they don't need?

Or will vaxport authoritarian madness carry on and expand into a medical social credit system and you'll get fired for not getting a flu shot every year and covid boosters forever? Will you be banned from attending University? Will you be barred from jobs. Will you be disallowed from travelling internationally or across certain state borders? The new regime of restrictions will serve no covid relevant purpose and protect no one from anything, but that doesn't mean they would stop the McCarthyist era style blacklisting of people. Oh you didn't get your flu shot and it was due last week, sorry you can't come into our restaurant?

I'd be predicting that such measures will become entrenched and slowly expand like most other forms of power creep. No one had or needed passports 150 years ago, but now everyone has to use them.

On the other hand, the good news is Pfizer will never have a negative quarter ever again with those Booster profits coming in, even if they have a pay out a few billion more in lawsuits from their criminal behaviour which results in people dying. Things are looking up for the upper class who will be able to buy into some system to skip the queue for all that vaxport stuff just like they can skip all the patriot act airport restrictions through buying a VIP pass.

I'd put this at 80% confidence....with the failure mode for more centralised power expanding would be some early and rapid defeat in the courts while they try to roll out their authoritarian plans further and further. So almost 100% the government will try, but maybe 80% chance they'll succeed. It isn't like any meaningful number of the patriot act era rights removals were ever restored. Will China take over the US's global leadership role or will the US simply become China through a medical apartheid?

Expand full comment

I believe that this latest trend in destroying the control/placebo group is terrible. While they argue that the net benefit to the (in this case 612 users) control group is too great to ethically continue, significantly more than 612 potential consumers wont trust the drug because of it.

I expect this will become the "status quo" in drug testing moving forward, and it will only be a matter of time until a major problem hurts a large population.

Expand full comment

Halting trials for futility / efficacy goes back at least 20 years, hardly the "latest trend".

Expand full comment

Speaking of predictions - anyone care to speculate what will happen once it is approved? Will anti-vaxers refuse to take it? Will its use get politicized? Will it end the pandemic so I can get my former happy life back?

Expand full comment

Sure: 1 )Yes, 2) Obviously, 3) Probably not. If the antivax covid deniers don't trust the Pfizer vaccine, why would they trust the Pfizer medication? Bill Gates clearly recognized that his ploy to microchip the entire population with the vaccine wasn't working, so Pfizer came up with a different fake drug that they're pushing on antivaxxers, claiming it's safe "because it's not a vaccine", when it is in fact also mind-controlling people into accepting the New World Order. Massive /s, by the way.

I suspect it will take quite some time before paxlovid is in every first-world pharmacy, and even when it is, its availability will not stop covid from spreading, it just makes it treatable. So I expect that governments will keep insisting on masks and social distancing but the actual populace will chill out now that there's less risk of serious illness and death. The effect on long covid remains to be seen though.

Expand full comment

There's an obvious difference between a preventative medicine you take when you're not sick in order to avoid getting sick, and a treatment you take after you're sick. People can pass on the former banking on just not getting sick, but then once they actually get sick there isn't really an optimistic path for not taking the drug.

Expand full comment

"but then once they actually get sick there isn't really an optimistic path for not taking the drug."

Sure there is. You figure you're not going to get any sicker.

Expand full comment

Even if you're in the ER?

Expand full comment

Looking at what Pfizer say in their press release, it's not for general use, it's for people with underlying conditions:

https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate

"Enrolled individuals had a laboratory-confirmed diagnosis of SARS-CoV-2 infection within a five-day period with mild to moderate symptoms and were required to have at least one characteristic or underlying medical condition associated with an increased risk of developing severe illness from COVID-19."

So if you're not a high-risk adult, this drug is not for you and won't affect the general precautions around transmission, vaccination, etc. This isn't a cure, it's "if you have contracted Covid, have a co-morbidity, and are likely to get badly ill and need to go to hospital, this will reduce your chances of that need".

" Upon successful completion of the remainder of the EPIC clinical development program and subject to approval or authorization, it could be prescribed more broadly as an at-home treatment to help reduce illness severity, hospitalizations, and deaths, as well as reduce the probability of infection following exposure, among adults."

Expand full comment

Hmm, so that tips question 3 towards 'probably not' even more.

Expand full comment

I think we won't know exactly how effective it is for the general population (haven't got Covid, have got it, have got it severely and so on) until it gets approved and is distributed out 'in the wild' so to speak.

It may be as good as it sounds, or it may not. It may be "this stopped me having to go into hospital" for some people, and "it helped me get better in nine days instead of twelve" for others.

I think there's a level of hysteria around Covid that makes me very wary of demands to "let everyone take this, that, or the other miracle cure now!" demands, because you know as well as I that it is human nature to go, if and when any problems crop up, "why did you let this unsafe drug be released to the public?" by the same people demanding it was released immediately.

Expand full comment

You're confusing the exclusion criteria for the trial with whatever indications FDA and Pfizer agree to for the label. It may well be approved for anyone with Covid19 symptoms. And, the trial that press release refers to is only one of 11, with 7 on-going, several of which are designed to explore the efficacy / safety in various populations.

Expand full comment

"approved for anyone with symptoms"

Sure, I agree this is likely; it will be the market to reward the pharma company, after all, and nobody ever refused money.

But giving it to non-high risk/non-severe cases also means "people who were never likely to develop severe problems", so they're not the ones who are "if they don't get this, they will die and their deaths will lie at the door of the FDA!!!!" people are talking about in this thread and so the whole "having to wait longer to get it" doesn't make a life-or-death difference to them.

If it's prescribed for the non-high risk as a precautionary measure along with "so long as you're vaccinated and got your booster dose and are following social distancing etc.", I have no objection. I just think "rush it out and the devil take the hindmost" is only an argument which is strong for "this prevents deaths", not "this will reduce your symptoms by a day or three".

Expand full comment

> If the antivax covid deniers don't trust the Pfizer vaccine, why would they trust the Pfizer medication?

Something like 20% of anti-vaxxers are due to fear of needles, so a good chunk would arguably take it a drug like this.

Expand full comment

A quick look at clinicaltrials.gov shows 11 studies, 7 still in progress, concerning PF-07321332/ritonavir. Some are designed to look specifically at plausible bad interactions with common drugs. It's nice if the efficacy trial with ~1000 patients doesn't show any random safety problems, but it would be malpractice to not complete the safety tests on plausible bad drug interactions before unleashing it into a population that's going to be using it together with 100's of other drugs. Would you approve a drug without even a small test on people with hepatic impairment?

Expand full comment

And to be clear, the phase 2/3 trial specifically excluded those plausibly bad situations, like "Known medical history of liver disease", "Receiving dialysis or have known renal impairment", or "Current or expected use of any medications or substances that are highly dependent on Cytochrome P450 3A4 (CYP3A4) for clearance or are strong inducers of CYP3A4".

Expand full comment

Good point! I would probably pre-approve it for people without such an impairment (i.e. for people similar enough to the trial participants). Although that may give way to "this drug is dangerous for people with hepatic impairment, etc." meme, which would be hard to kill once (and if) it's established to not be the case.

Expand full comment

Am I the first to notice that the name is too damn similar to the drug in the fiction series Firefly? The one with rather extreme effects not noticed unless after distribution? A rather poor name choice for something we want hastily approved.

https://firefly.fandom.com/wiki/G-23_Paxilon_Hydrochlorate

Expand full comment

Oh no! I can see the memes now.

Expand full comment

The basic point is clear. It's not just covid. Should trials of any drug be suspended before FDA approval? What is the decision point?

Expand full comment

The argument that it is silly to stop the trial and then drag your foot with approval is strong (but there is a good comment below about the scaled up production process etc.).

But more generally, it sounds a bit polemic to me to speculate that the FDA is concerned with its reputation. Maybe at stake is not the reputation of the FDA, but the reputation of the approval process? Assume the case a drug is approved "prematurely" and saves 30000 lives but completely unexpectedly kills 10000 patients (who would otherwise have survived). What sounds like a great net positive outcome might still be very negative on the long term: Many people might lose trust in approved medication or evidence bases medicine in general.

Also, I am a bit surprised that Scott seems to use "expected value" so freely in this context. Medical ethics does not seem to work that way at all? At least, there seems to be a heavy asymmetry between action and non-action, maybe that is reflected in the approval system as well?)

Expand full comment

Classic Trolly Problem. Kill 5 people through inaction, or take action that kills 1 person? "Expected value" analysis would have you take action to kill 1 person to save one person and a mouse.

Expand full comment

A more concrete example: assume the existing covid vaccines saved 200K lives. Assume (just a counterfactual argument!) it killed 80K people. I think this could not be summarized with "120K lives saved, great!", and would be a desaster compared to, e.g., another vaccine that saves 120K people and kills a handfull...

Expand full comment

How much is it worth for someone within the FDA to send this article to whatever the largest internal distribution list they can find is? Assuming they don't care about lives and just about being compensated for reputational damage, wondering whether lives * p(anything more happening | internal annoying emails) > happy price. Not re: me, I'd just do it. :D

Expand full comment

"I care about maximizing expected lives saved more than I care about my reputation. Can the FDA say the same?"

Goodness, of course not. You're a mortal, with a finite influence and finite time, and by and by you will be replaced no matter what and your reputation will be of interest only to historians, at best. The FDA is immortal, and their reputation colors everything their future self does indefinitely. And it is actually *way* more important that generations of future Americans trust the FDA than that even as many as 50,000 lives in the present are saved -- because there are way, way more than 50,000 future lives at stake.

I'm not taking a position on how fast the FDA should approve this drug, but I am saying I think that your statement is too facile by half, and fails to acknowledge the importance of maintaining institutional trust[1] in an area in which people by nature have strong feelings. That is, and very well should be, a major priority at the FDA.

-----------------------

[1] I mean, would you even be feeling like you had to write a long screed on ivermectin, or fend off vaccine folklore, if institutional trust *hadn't* been lately damaged? Expensive, is it not, that kind of damage?

Expand full comment

Totally agree!

Expand full comment

We're all hurlers on the ditch here, it's easy for us to say what the FDA should or shouldn't do.

If, in the morning, we got the responsibility that "your decision on this will affect the health and lives of millions of people, even hundreds of millions; if you get this wrong, people will die - and getting it wrong means 'waiting too long to approve it' *and* 'rushing it out before all the data is in', so it's all in your hands" - how confident then would we be about "plainly the best course of action is X"?

Expand full comment

Exactly. Responsibility's a bitch, and real decisions never as black/white as it looks from the armchair.

Expand full comment

The FDA does not conduct studies on how their own actions affect their institutional trust and the reaction of the public. Hence doing things like the "pause" on J&J which resulted in a sharp drop in vaccinations.

Expand full comment

what evidence do you have that EUAing something a few weeks/months earlier will decrease institutional trust or trust in the FDA in the event of a mishap? [Also note, more importantly, the prior probability of a mishap for a drug that's passed through Phases 1-3 seems very, very low to me].

You have near certainty based on basic math that 10s of thousands will die if you delay for a few weeks vs no data to support the idea that trust will be affected in a way that offsets that.

That same argument was used when we were waiting for Pfizer to be approved last August, after stellar Phase 2 results and then again when we were waiting after Pfizer hit their end-points successfully on Nov 8th (see my timeline: https://moreisdifferent.substack.com/p/what-happened-a-timeline-on-the-development)

The reasoning people gave to justify the FDA's delays was "it will damage confidence if we move too quickly". I don't see any evidence for that. The anti-vaxers were going to complain the FDA moved too fast either way.

Also, there's a big difference between EUA and full approval. People aren't dumb and they recognize that. I would argue, as Scott did in his Aducanumab post, there should multiple tiers of approval. Also note the trial on Paxlovid will continue and they will continue to monitor for side effects and can easily revoke the EUA later.

The FDA's revoke of their EUA for hydroxychloroquine definitely tarnished their reputation at the time but you don't see people talking about it any more.

Expand full comment

As an ivermectin supporter I just want to signal support for paxlovid.

As a conspiracy theorist, I do suspect it's just a rebranding of ivermectin (new molecule, same mechanism of action), but in any case, it Works! Let's use it! This isn't a left right divide, this shouldn't be any sort of X/Y divide, everyone likes paxlovid! Yay paxlovid!

Expand full comment

Easy, I'll just give my horse paxlovid, and see if that solves his worm problem!

Expand full comment

This is really an asinine post. Why doesn't a regulator that chooses between life and death move faster and break things? The answer is inherent in the question. Calm down and let them do their jobs. When you push harder and criticize them, aren't you begging them to screw up? And at that point, your tune will change to griping about how they make bad decisions. Being a two-bit critic on the internet seems a lot easier than actually having responsibilities over human lives.

Expand full comment

Scott's point is that the FDA could plausibly move faster and *not* break things, given that by their own standards, the pill is so effective that it's unethical to continue trials. To be fair, people in the comments have brought up two possible reasons why they're not immediately approving it:

- The pill is supply-limited*, so approving it sooner won't increase the total number of people who get it. (Although depending on how they plan to distribute it, there may be a tradeoff between targeting some at-risk people now + some at-risk people later, and at-risk people later + less-at-risk people later.)

- The FDA might need additional time to review the manufacturing process and make sure that all pills produced in the future will be made to the same quality as the first batch. (I haven't actually seen this mentioned as a bottleneck in any other articles/sources--all of them have emphasized reviewing data only--so I'm not sure how likely this is.)

However, I think it says a lot about the FDA that I wouldn't expect their process to go any faster even if both excuses were invalid. IMO, their track record on speed (no vaccine challenge trials, long review periods for the EUAs as mentioned in one of the linked articles**, more long review periods for half-doses and vaccine combinations, more long review periods for boosters...) hasn't been exceptional during the pandemic. They could be doing worse, but I think they could also be doing better, and I think it's absolutely fair to criticize them if this is true.

*https://www.nytimes.com/2021/11/16/business/pfizer-covid-pill-paxlovid-unvaccinated.html

**https://thedispatch.com/p/fda-career-staff-are-delaying-the

Expand full comment

Realistically speaking, it's probably irrelevant whether they approve it now or in two months unless the drug has a very short shelf life, as they won't have enough of the drug to go around for a while due to having to work at ramping up production of it. Even if it was approved right now, I'm not sure if it would even save net lives.

They're probably using that time to make sure manufacturing is up to snuff and maybe looking over the data a few more times to make sure they didn't overlook something stupid.

The reason why we didn't immediately start mass inoculating people with experimental vaccines in 2020 wasn't because it couldn't save lives, it was that it could potentially cause serious issues with diminished trust if some of the vaccines didn't work, which could disincline people from taking the real ones.

The biggest downside of rushing out a medication is that it doesn't work and it erodes trust in future medications that do work.

Expand full comment

A secondary question is, when will the FDA or the EMA (European medical agency) approve Sinovac, which by now has been used 3 billion times or so.

Probably when their boards are no longer as heavily Pfizer dominated.

Expand full comment

Sinovac is the least effective vaccine. There's no reason to approve it.

Expand full comment

There is reason: It's a traditional inactivated virus vaccine. Vaccine hesitancy -- in many if not most cases -- hinges upon the fact that the Pfizer and Moderna vaccines are derived from untested new technologies which are somehow less trustworthy, and which might have side effects down the line. Giving people the option of taking a traditional vaccine, even if it is marginally less effective, should improve vaccine uptake. I know that a lot of people, given the choice, would take Sinovac over Moderna.

Expand full comment

Novavax should be approved outside the US fairly soon. Hopefully they get around to submitting to the FDA at some point

Expand full comment

Except there's no evidence that resistance to vaccination is driven by this at all.

Expand full comment

Why would there be?

Expand full comment

Well, countries using Sinovac for some reason outperform countries using western vaccines, if one accounts for adminstrative and medical capabilities in these countries?

Furthermore, Sinovac does massively force Covid to rapidly alter its spike protein, also known as the protein where mutations are most likely to unlock new and unpleaseant capabilities, such as Delta apparently being able to infect cells via cell to cell contact.

Delta has 3 mutations on the spike protein, no mutations elsewhere. It apparently has new capabilities. We have Delta as dominant because we force Covid to mutate by using spike protein only vaccines.

Sociologically: If I, because otherwise I dont have a social life anymore, accept being bludgeoned into getting Pfizered, I show that I can be bullied into being forced to take a somewhat dangerous product, by the authorities, and the authorities do finanically benefit from it because I do not see a big difference between Pfizer and the government. This situation increases profits, and power for the authorities, so they will continue it in perpetuity.

If however I take Sinovac, then the authorities expend resources to bully me in order to make me send funds to their rivals. They will cease this bullying as soon as they can epidemiologically, because it makes no financial sense for them.

This is just how authoritarian entities work. The west is moving into a heavily authoritarian direction. Bending over to the authorities will accelerate this unfortunate effect.

Expand full comment

My understanding is that Delta doesn't have much vaccine escape. It got selected because it's more transmissable TO THE UNVACCINATED.

Expand full comment

It's higher than Alpha, lower than Beta:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442750/

Expand full comment

Except every part of this is false?

A number of countries using Sinovac have had significant issues and much higher breakthrough infection rates than the US.

Moreover, we target the spike proteins because they're the outer part of the virus and thus are the things that are easiest for the immune system to target and effect. Your understanding of evolution is wrong.

Society operates on the principle of reciprocal altruism. You are not engaging in reciprocal altruism.

You are projecting your own inner desire to hurt and oppress other people onto others. The idea that this is somehow going to "compromise" you is nonsensical.

Expand full comment

Your own CDC:

https://www.cdc.gov/mmwr/volumes/70/wr/mm7034e3.htm

Effectiveness vs Delta is down to 50%, as theoretical immunology would predict when you only present one protein and a variant where this protein has 3 mutations occurrs.

This is known since august, even in non specialist outlets like Bloomberg.

https://www.bloomberg.com/news/articles/2021-08-24/vaccine-efficacy-diminished-as-delta-arose-cdc-report-shows

Anyone with any understanding of evolution could have told you that, especially if they co authored papers on somatic hypermutation in germinal centers, which I did and you did not.

Law of value of theoretical immunology: If theoretical immunology says something should not work, it is highly likely to not work. If theoretical immunology says something should work, this sadly means nothing whatsorever in terms of prediction on wether it works or not.

And I am not hurting or repressing anyone, nor do I have any desire to do so.

Stop projecting yourself.

Expand full comment

From what we can tell, giving people boosters seems to restore the full level of initial immunity, or possibly even higher.

Look at this graph:

https://i.insider.com/619d6389d2fd62001820c2ae?width=700&format=jpeg&auto=webp

That would suggest that the booster made people who got the booster roughly an order of magnitude better off than those who did not. That's the difference between 50% efficacy and 95% efficacy (or better, possibly).

If the decline in efficacy was due to mutations, we would expect that we should see waning benefits across the board - both in newly vaccinated people and in people who have long since been vaccinated.

However, what we instead seem to see is that there's a temporal element involved - indeed, the front line workers were the first people to be vaccinated, and thus, were the people who would have seen the largest decline in immunization efficacy.

The data is consistent with the decline being driven not by mutations to the spike protein but by time from first vaccination - in fact, there is no data available that suggests otherwise.

That doesn't mean that mutations aren't concerning, but the breakthrough rate appears to tank badly post booster, which is exactly what you'd expect if the vaccine remains effective but immunity wanes over time, but is inconsistent with the notion that the vaccine doesn't work against Delta.

Moreover, we can see from real world data that people who were infected by *actual COVID-19* and thus were exposed to the whole shebang are *more* likely to get reinfected than people who were vaccinated. This points against the notion that different types of vaccines will yield better results - actually getting sick seems to give *worse* immunity, so there's no reason to believe that other sorts of vaccine will actually be any more effective.

On top of that, there's the additional fact that other proteins may not even be recognized by the body very well because the antibodies have a harder time getting at those versus the spike proteins.

On top of everything else, because the virus has been multiplying mostly in unvaccinated populations, the biggest evolutionary incentive is to evolve against previous infection being protective.

Targeting the spike protein has other advantages as well. The spike protein is a virus fusion protein and is key to the virus being able to actually interface with cells to infect them; there's a limit to how much mutation is even possible on it without it no longer being able to fulfill its primary function of binding onto cells, which is another reason why it is being targeted - mutations that make it better at avoiding the vaccine may well make it worse at actually infecting cells, which makes it harder for evolutionary pressure to modify these proteins because mutations to these proteins can often result in the virus simply no longer being able to infect cells at all - at which point it doesn't matter if it can't be detected by the same antibodies.

> Anyone with any understanding of evolution could have told you that

I understand evolution better than you do, given your apparent magical beliefs about how something can "force" something to evolve in a particular way. That's not how evolution works. Evolution is not an intelligent force, it is a probabilistic thing. But there are major constraints on what it can and cannot do. It cannot simply create novel mutations ex nilho, and oftentimes mutations have trade-offs - whatever the virus is doing, it has to be able to bind with cells, which limits how much the spike protein can change without rendering the virus unable to do that.

> especially if they co authored papers on somatic hypermutation in germinal centers, which I did and you did not.

I wonder if your papers were some of the sloppy things we tore apart in my molecular virology class at Vanderbilt. I mean, some of the things that people publish is utter trash. In fact, more than half of it is.

Why do you believe you aren't in that half?

I mean, did you spend any time whatsoever focusing on why you might be wrong?

Because you don't seem to have even bothered looking for evidence that you are wrong about this, even though the obvious alternative hypothesis (waning immunity due to time, not mutations to the virus) was sitting right there in front of you.

Why, if the virus mutations are causing the vaccine to fail, does the vaccine's efficacy seem to have a significant time-based component to it? People who are freshly vaccinated appear to be significantly less likely to get sick in the data we have available, which is at odds with the idea that mutations are rendering the vaccine significantly less effective in general, and is entirely consistent with the idea that immunity wanes temporally.

Expand full comment

"Least effective" can still be better than nothing.

Expand full comment

They generally require you to beat what's presently on the market to be approved. One of the reasons why it is harder to get medications approved this day is that a lot of them just aren't better than existing options.

Expand full comment

They will never approve Sinovac because of reasons of vaccine nationalism that have been on display all through the pandemic (that's part of the reason they never approved AstraZeneca, I believe).

A better question is what about Novavax? The first Phase 3 results came out in the late spring and were really good and since then lots more Phase 3 results have piled up. Yet the FDA hasn't given the OK to Novavax to submit their application. There are a lot of people waiting for Novavax because the mechanism of action doesn't involve using mRNA or DNA like the current vaccines do (they basically just inject you with spike proteins).

Expand full comment

AstraZeneca was being super shady about their data. It's not surprising that the FDA has not been kind to them.

Novavax is chugging through and will probably be approved at some point.

And there's no evidence that any of these things will make any difference.

Expand full comment

The best moral argument I can construct for treating the control group and the population at large differently is that the control group has accepted some degree of risk in enrolling in the trial. Therefore they have provided the identical informed consent as the trial participants that are not control, while the population at large has not, and perhaps in some understanding of the facts cannot. The control group would in this argument not be morally equivalent to the population and low probability, yet-to-be discovered hazards can ethically burden the control group but not the population, assuming of course the control group has served their end in providing adequate data for the evaluation process.

I suspect the answer has more to do with some implicit assumptions about a difference between causing harm (active and specific) and allowing harm to take place (passive and diffuse). But that’s speculation.

Expand full comment

The thing is, remember the news coming out about blood clotting side-effects from the AstraZeneca vaccine? That only came out as mass vaccination started, because the effect was so rare and they just didn't catch it in the limited number of people they had in the trials.

https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood

And there's a lot of conspiracy theorising about current vaccines and infertility and the like, even if this is extremely unlikely.

So - you rush approve this new oral anti-viral treatment based on how well the trials went, then later on it turns out that once it's been tried on a couple of million people world-wide, as distinct from a couple of thousand people in the trials, a very rare but concerning side-effect shows up. Maybe even people die from it:

https://blog.ons.gov.uk/2021/10/04/how-many-people-have-died-as-a-result-of-a-covid-19-vaccine/

"In contrast, the different statistical agencies have reported that to August 2021 (June 2021 in Northern Ireland) there were 4 deaths in England, 0 deaths in Wales, 4 deaths in Scotland and 1 in Northern Ireland. Of these, 4 in Scotland and 1 in Northern Ireland had the vaccine as the underlying cause of death. This meant that there were 9 deaths in the UK that involved the vaccine (meaning the vaccine contributed to the death), of which 5 had the vaccine as the underlying cause (meaning the vaccine initiated the chain of events directly leading to the death). For these deaths, there was evidence to suggest that the vaccine played a part in the chain of events that led to the death."

That's only a very few deaths, but maybe people become very concerned that *anyone* died from what was supposed to be a safe vaccine. And maybe that feeds into the anti-vaccination campaigns.

So the FDA has to balance caution with the requirement for haste: wait too long, and deaths that might have been prevented may happen. Go too soon, and deaths that might have been prevented may happen.

Expand full comment

Maybe you even get questions asked in parliament about it, which imply that you *should* stop the rollout of vaccines!

https://www.europarl.europa.eu/doceo/document/P-9-2021-004862_EN.html#def2

"Three young people recently lost their lives after receiving their second dose of the COVID vaccine. These cases are the latest to be added to the growing list of sudden deaths to occur during the vaccine rollout.

The recent autopsy report for Camilla Canepa, who also died following vaccination, stated that the cause of death could be ‘reasonably attributed to an adverse effect from administration of the COVID vaccine’.

A German study examining the autopsies of people who died shortly after vaccination suggests that 50% of these deaths were caused by the vaccine, which is also believed to be behind an unprecedented accumulation of lymphocytes found in the hearts, kidneys, livers and spleens of the deceased.

In the light of the above:

1. Does the Commission intend to reanalyse the costs and benefits of vaccinating young people, given the absolute risk of serious – or even fatal – adverse effects?

2. Will it withdraw the emergency use authorisation for the vaccines – at least for the under-50s, for whom the serious risks associated with vaccination appear to outweigh the limited benefits?"

Expand full comment

I find it curious that some guy in his basement can legally sell a virtually untested LSD analogue online for months or years before the authorities get around to blacklisting it, but a company like Pfizer needs to wait for months for their drug to get whitelisted before selling any. So maybe the solution is for Pfizer to sell Paxlovid as a "research chemical" for home laboratory use :P

Expand full comment

Many people have made the convincing riposte to this post that as manufacturing capacity will be the limiting factor, it doesn't matter that much how long (within reason) the FDA takes to approve Paxlovid.

I don't think this is as convincing as it first appears - Paxlovid isn't like a vaccine where you pretty much want everybody treated asap. So a country like the UK orders 200 million doses and tries to get the jabs into arms just as quickly as punters and jabbers can be lined up.

The antiviral will be given to vulnerable people, after infection and after symptoms develop. Which explains why the UK has ordered only 200 thousand doses. You only need as many doses as people who are getting sick (+ a few 'just in case', to be on the safe side)

My point is that supply may well equal demand, in which case delaying approval goes back to being a really bad thing to do.

Expand full comment

I appreciate the bat post.

Expand full comment

I see this as a big problem, that only big business has enough resources to fund good clinical trials, because like this only treatments that promise good profits get rood evaluations. If anyone has a cheap or easy treatment gets just to hear 'It's not proven to work/be save, so shut up when the professionals talk'. So it's no wonder the costs of our health systems raise so fast.

Perhaps it would be a great project for ACXG+/++ to fund independent research or trials of promising cheap and easy treatments that are therefore not interesting for commercial research.

One Candidate i came across could be chlorine dioxide solution (CDS) as described here: https://akjournals.com/view/journals/2060/107/1/article-p1.xml

Expand full comment

Big takeaway is that Agencies do not design their procedures along cost-benefit lines, especially failing to consider the cost in time of the procedure.

Expand full comment

1) usually they don't design their procedures from scratch, but they evolve. So of course there are outdated part s you wouldn't design this way now. But redesigning a ageca comes with great cost and risks too so everyone lives with it.

2) time is usually not the big problem, so of cause it's not optimized for. Even if you hurry up health risks, risk to the general trust in the agency and legal risks are still important. Imagine next time a questionable medication getting pushed almost untested because there is a precedent just because there are some mistakes in the paperwork this time.

3) It's very easy to underestimate the work and effort needed in fields you know little about.

4) of cause it's all humans that also care for their prestige (not being to blame), ease of work and all the human connections involved.

So yes i agree that in theory this cold be done more efficient and much faster, but in practice i believe they are really doing what they can, and i doubt you can organize it so much better, given the complexity of the matter, legislation and amount of humans you have to involve.

Expand full comment

These are reason that regulations are not continually optimized. They do not reduce the costs of not being continually optimized.

Expand full comment

> 3) It's very easy to underestimate the work and effort needed in fields you know little about.

This reminds me of the person on DSL who was confused why Tech companies needed so many employees.

Expand full comment

Approval of Paxlovid sounds like a job for MINIPAX and MINILUV.

Expand full comment

I'm sure I'm not the first to convey this sentiment, but I'm a little confused by this post. We all already know that with any governance system there is a trade off between centralization of authority - let's call it "having an X (e.g. medical, financial, educational) Tsar", in keeping with SSC tradition - and having lots of checks and balances in a more distributed system, which I'll call democracy (yes, I know democracy entails other things as well, it's just an ad-hoc term).

The more Tsar you go, you can act more quickly, be flexible as a society and respond to extreme changes in your environment. The down side is, if the Tsars themselves are human, they are prone to errors, corruption, or any other lapses of judgement, and can fail miserably. The more democratic you go, the more stable you are, with less chance for catastrophes of that sort, but unreactive and sluggish on the down side.

Current western society is not in the optimal point in this trad-off, probably a little too democratic. The way this manifests in reality is that the FDA will take six weeks to approve a drug that everybody agrees is effective. Not a year, mind you, six weeks, which to me sounds like a completely reasonable time to push papers hastily for a federal entity. And that's ok, cause what we earn by sacrificing speed is the up-side of a more democratic process (more insurance against huge errors).

So basically the entire point of the post can be summarized to "I wish we could move more towards the optimum, here's an example that makes this point very clearly." Well, yeah, but designing regime schemes is really hard. If we have a better solution to this (like earlier posts about the FDA) than awesome, let's discuss the solutions themselves and see how viable and effective they might actually be. If we don't, there's not really much to say.

Either way I'm not sure another example deserves its own post, and should, imo, be presented in the right context. Maybe a list of facts demonstrating how the US is too democratic (in the sense defined above) and not Tsar enough. Or just the FDA. Preferably, if there's also a list of opposite examples such that in time, we can try and compare the two.

Expand full comment

Using the term "democracy" to refer to the permanent unelected bureaucracy seems bizarre. Having the elected President authorized to force them to do what he tells them to would actually be MORE democratic!

Expand full comment

I agree haha, I debated using bureaucratic but that seems off too, cause the point of a bureaucracy isn't always to avoid catastrophe through checks and balances (a term which always makes me think about studying democracies in civics class).

Expand full comment

None of our bureaucratic agencies are designed for "checks and balances". They are all part of the executive branch, run by the President. It is the other branches of government that are supposed to check each other.

Expand full comment

Your analysis is roughly right in normal times (it's too influenced by pressure from congress / too democratic and beaurocratic). But under a declared state of emergency, the EUA legislation makes the HHS Secretary a "Czar" and gives them power to issue EUA. All the legislation requires is that " it is reasonable to believe that—

(A)the product may be effective in diagnosing, treating, or preventing—

(i)such disease or condition; or" and "the known and potential benefits of the product, when used to diagnose, prevent, or treat such disease or condition, outweigh the known and potential risks of the product, taking into consideration the material threat posed by the agent or agents identified "

You can read the full text here : https://www.law.cornell.edu/uscode/text/21/360bbb-3

Expand full comment

Of course, but I'm don't know how much time even that rushed process usually takes, and what other precautions the FDA have to take into account (there are some good comments here on scaling, for example).

I'm just saying that whatever they are doing, not necessarily in this case - it is possible that in a bureaucratic society, such things take more time than we would have wanted, even when employing rushed procedures. There's a cost to the fact that the infrastructure itself - the institutions and the MOs they usually optimize for - are slower than we'd like in an emergency, cause most times aren't an emergency. And I'm saying that's to be expected, cause we get other benefits from using this particular institutional model. If we were a society built on Tsars, that optimizes for fast and agile reactions and total commitment to a single cause, we would perform worse in non-emergency times.

And again, obviously we are not at the optimum of this trade off (in the US or anywhere else), but I don't see much point just declaring that, without discussion of an alternative.

(all of this was only a reply to scott saying that he wants to live in a world where it doesn't take 6 weeks, there are of course other parts of the post which I agree with/found interesting)

Expand full comment

Would be nice if stopping trials for this reason resulted in an immediate EUA. You can retract later if new data conflicts, but at least it's legal to use in the meantime.

Expand full comment

"Perhaps there’s not enough evidence for the FDA to be sure Paxlovid works yet? But then why did they agree to stop the trial that was gathering the evidence?"

Researchers run on one system of ethics while the FDA runs on another.

I'm reminded of some old episodes of M.A.S.H where the main characters who were treating some injured POW's complained about the government not being able to decide whether they wanted to blow up these young people or put them back together in light of paying to do both.

Expand full comment

Just popped by to say the word “manufacturing”, but I see Andrew beat me to it. Good show, Andrew!

Expand full comment

" it’s pretty weird that the FDA agrees Paxlovid is so great that it’s unethical to study it further because it would be unconscionable to design a study with a no-Paxlovid control group - but also, the FDA has not approved Paxlovid, it remains illegal, and nobody is allowed to use it."

Possibly because Pfizer may have been a little bit naughty (allegedly!) in releasing all the data on their own vaccine trials, so the FDA are being careful not to simply rubber-stamp something a pharma company tells them?

https://www.bmj.com/content/375/bmj.n2635

Expand full comment

FWIW, my wife was prescribed Ivermectin by her doctor recently (for something unrelated to Covid or worms) and basically no pharmacies in our (large metropolitan) area would fill the prescription.

Expand full comment

What was it for if not parasites?

Expand full comment

Some lingering, unknown virus that she just couldn't kick. We did finally get the prescription filled and it at least coincided with everything clearing up

Expand full comment

Was it lack of availability, or because they thought "ha ha🐴 "?

Expand full comment

90% sure it was the latter

Expand full comment

The delay is explained by Parkinson's Law: work expands to fill the time allotted to it.

Expand full comment

Problems with this approach: if followed, manufacturers could have an incentive to submit poorly designed studies and profit from the distribution until the application is rejected. This in turn will cannibalize the proper testing and development of effective treatments.

This piece also neglects that the monoclonal antibody treatment is available and people taking an ineffective medicine would be denied such treatment.

Finally, this piece misses a discussion of what goes into the approval process so one can identify which steps could be skipped and what the tradeoffs are.

Expand full comment

"if followed, manufacturers could have an incentive to submit poorly designed studies and profit from the distribution until the application is rejected." - Please keep in mind we are talking about a rare exceptional emergency action for EUA here, not a general rule change. And also there are market incentives against doing what you describe.

"This piece also neglects that the monoclonal antibody treatment is available " It's been pretty common knowledge for at least a year that monoclonals are all in extremely short supply, and this was expected all along b/c they are hard to manufacture. The waitlist at our local small-town hospital for Regeneron's monoclonal is 30 patients long.

Expand full comment

"Heck, people can get ivermectin even without a prescription as long as they use the veterinary version."

—people have, and ended up in the hospital, due to the dosage being way different and marine also the inactive ingredients. If you're mentioning the vet version you should mention that

Expand full comment

*marine = maybe

Expand full comment

If they stopped the trial prematurely due to effectiveness, then it is 99% guaranteed that the FDA will approve the drug. The threshold is much lower than for vaccines because this drug will be given to people who are sick and at risk of severe disease.

The reason for the delay is most likely that it takes a lot of time for FDA to review all the paperwork. The approval process includes a lot of validation. It is not only the trial results but every step related to manufacturing and ending with labelling. The pharma company first need to develop the scaled-up manufacturing process, validate all assays to show that the manufactured drug is what it says it is, free from impurities and at correct active substance content. Document all these validations and then reviewed by the FDA who will probably request some corrections and changes. Unfortunately, it takes quite a lot of time.

I guess that the prediction market is mostly right and possibly insiders already know tentative date of approval anyway. Unless the pharma company had done this preparation work in advance (someone knows for sure), the market predicted date should be approximately correct.

Expand full comment

for some context Re; Andre's update:

52 NDA - new drug applications are being held up due to a back log in the FDA conducting inspections of the sponsors (owners of the drug in question) and of the manufacturing facilities (not always the same as the owner of the asset). many biopharma companies use outsourced manufacturing - in many cases for both production of clinical trial materials & commercial products).

https://twitter.com/ZacharyBrennan/status/1462867968816300040

also, your PPS comment is provably false. There have been numerous cases in which hospitals have blocked the administration of ivermectin for covid patients - most notably in the recent case involving Dr Pier Kory's colleague Dr Paul Marik. Marik's case is interesting because it is not just IVM but all early treatments being prohibited by his medical administrators.

Also, the 'horse dewormer' propaganda campaign against IVM waged by the FDA, mainstream media among others is certainly an odd happening notably while the NIH confirms that IVM is being researched in clinical studies about its effectiveness against covid. a review of clinicaltrials.gov or the NIH's website confirms these facts.

Expand full comment

very interesting , thanks for the tweet!

I suspect a lot of the backlog is because the FDA forbade inspectors from traveling via plane during the pandemic (even though other essential people like grocery store clerks etc were working in high risk environments). It created a huge mess, resulting in cancer patients not able to get the drugs they need, etc https://marginalrevolution.com/marginalrevolution/2021/03/fda-postpones-inspections-delaying-new-drugs-and-creating-shortages-of-old-drugs.html

Expand full comment

Safe to say Scott sold out and also lost 30 IQ points.

Was leaning that way after the Ivermectin post and now I'm 100% sure.

Unsubscribed from this garbage.

Expand full comment

I don't understand. Where is the mistake in his reasoning?

Expand full comment

Allow me to speed you on your way with a hearty goodnight, goodbye and good luck, and if you want to dose yourself on every 'miracle cure' recommended online, knock yourself out, buddy, but please first make sure you write it into your will to leave your body to science.

Expand full comment

typical Big Pharma, taking Louis C. K. away, but here, have Ali Wong

Expand full comment

It does seem like there ought to be some sort of “we have no reason to think this doesn’t work, go ahead and use it at risk while we review the paperwork” pathway for active pandemics.

I mean, they are waiting weeks to just have the Zoom call to decide whether to give it an EUA. That’s insane.

Expand full comment

From the outside, it does seem like reputation risk, as Scott mentions, is a big problem at the FDA. I can somewhat understand their point of view. If people lose trust in the FDA's actual decisions (beyond just the current groups of critics), rather than mostly critiquing their inactivity, I could see how they would believe that would be more damaging to their societal authority as a regulatory body. But more transparency is a better solution than dragging their feet and being opaque. I would propose they make faster decisions, even if they're sometimes wrong, and publish public post-mortems on decisions, good and bad, to show the public that they're paying attention to the process and seeking to improve it. I think FDA reform could give us faster action and a stronger reputation for the FDA, rather than trading those two off as the FDA seems to believe is the case.

Expand full comment

I do have an inclination towards the FDA's side, since if they make a wrong decision sometimes, this will have a huge impact on people's health.

Apple ship a new phone where the screen melts if you go out in direct sunlight? Oops, very expensive and inconvenient, but nothing worse.

FDA approve a drug where you melt if you go out in direct sunlight? A lot worse and "Oops, got that one wrong" is no consolation.

Expand full comment

FDA fails to approve (or delays in approving) a new drug that saves lives? People die, but nobody at the FDA gets blamed or loses their job.

Expand full comment

Transparency is only beneficial when outsiders are acting in good faith. Otherwise, they'll just find something to take out of context and use it as more ammunition against you. Scott should know this first hand,

Expand full comment

"But then how come the prediction markets are already 90% sure what decision they’ll make?" -- this seems to say that the prediction markets think there's a 10% chance it won't be approved at all. 10% is a sizeable number, why are we all suddenly so dead certain that it needs to be treated as 0?

(My issue right now is that it seems like we would've observed short-term side effects already, and I'm not sure an extra month will let us observe any long-term ones -- but this might be a false dichotomy, I really don't trust my intuitions on this enough to start screaming STOP THE TRIALS ALREADY. The CFR for Covid is not humongous, so it doesn't take a hugely common side effect for it to have the potential of outnumbering the Covid death toll.)

Expand full comment

I think 10% is being reasonably cautious. It's highly unlikely, but it is possible that everything will look like plain sailing up till the last minute, and then something will come out to upset the apple-cart. Maybe some of the triallists will show up with strange symptoms, or there will be a problem scaling-up manufacture.

Expand full comment

"Molnupiravir is saving lives in the United Kingdom; the FDA is blocking it here.

"If clinical trial results are accurate, another antiviral pill (Paxlovid) reduces the risk of hospitalization and death among high-risk COVID patients by 89%. If other countries approve it first, patients will again lose precious time as the FDA denies them the right to access the drug on the strength of those approvals."

https://www.nydailynews.com/opinion/ny-oped-fda-fails-american-patients-20211109-d2zzig2ounflbgczympfwrtp3u-story.html

Expand full comment

From prototype (trials) to ultra large scale production (a pill for billions of humans) typically it takes quite some time. The naive western imagination yet is that a clever engineer throws a blue print for any product over the fence to the factory - typically seen imagined as a cheap Chinese factory full of dumb human robots. Days or weeks later a huge amounts of containers of a perfect shiny product - a perfect incarnation of the blueprint is thrown back over the fence to the engineer and sales of perfect products is skyrocketing like hell. "And they all lived happily everafter"

Back to the reality of products, their development and scaling: its a mess and a hell (see "production hell" https://observer.com/2019/02/elon-musk-tesla-production-hell-podcast-interview/)

I'm neither from chemistry nor from big pharma but from R&D & scaling *not safety critical* electronic products. Let me phrase it like this: We researchers and engineers are naive and have no clue at all about the reality of (ultra) large scale production. Period.

An immense number of issues never thought of or foreseen by engineering to bee resolved and fixed by production teams. Engineers will quite often never receive any info about these issues.

So I would expect the same in pharma especially if its about ultra high scale and during a pandemie when literally millions of people die.

Just as a reminder https://en.wikipedia.org/wiki/Thalidomide_scandal

Clinical trials showed no issues but years later the super gau had happened:

"In the late 1950s and early 1960s, the use of thalidomide in 46 countries by women who were pregnant or who subsequently became pregnant, resulted in the "biggest man‐made medical disaster ever," resulting in more than 10,000 children born with a range of severe deformities, such as phocomelia, as well as thousands of miscarriages."

Root cause is a synthetic molecule which is synthetisised at the same time in the correct 3D orientation and in the mirrored 3D orientation (enantiomer):

"Different effect of (S)- and (R)-enantiomer

Sequence of racemization

The two enantiomers of thalidomide: Left: (S)-thalidomide Right: (R)-thalidomide

Thalidomide is a chiral compound that was sold as a racemate. The sedative effect is attributed to the (+)-(R)-enantiomer,[36] the fruit-damaging effect is attributed to the (-)-(S)-enantiomer"

So lets hope the best...

Expand full comment

Can someone tell me what happened to Remdesivir?

It doesn't really work right? At least according to a review from Cochrane and the WHO.

Or at least: It doesn't really work as much as we hoped to?

So what happened? How come the drug that got approved by the FDA and which was used to treat the President of the United states no less is somehow close to worthless now?

And what is the likelihood that the same thing could happen to Paxlovid and Molnupiravir?

Has someone looked at it?

I am sorry my comment has more questions than anything. But judging the effectiveness of drugs seems to be a really really hard thing to get right (also considering the whole Ivermectin debacle).

Expand full comment

Two answers:

1) Commercial pharma companies have a lot of incentives to get products into the market which do no observable harm, which are patentable, which can be easily monetized over a long period of time, to just modify older molecules slightly so that it can be patented as a new product for another 20 years. They have less incentives that their products are curing with only one pill, are curing at all, are not making things worse in the long run for the consumers. I'm not blaming them, just nowing about the incentives which are mostly Like they are. So a legal medication which has nearly no or no effect at all can be seen a lot.

2) Regarding general antiviral medication: Roche Tamiflu was stockpiled for billions by multiple governments during the swine flu outbreak years ago. It turned out that Roche had conducted thousands of 'studies' to just by chance end with some which pretend Tamiflu is effective as a antiviral treatment. They effectly rolled 10 dices 10000x to get some random 'all six' an pretend all their dices always show a six.

Turned out that Tamiflu is not only not effective but also dangerous. A lot of Japanese children on Tamiflu commuted suicides.

Expand full comment

This is what bothers me the most in this debate.

I agree that Ivermectin probably doesn't work (or only very little and only in some circumstances). It would be great if it would, but it probably doesn't.

But seeing your answer critics and ivermectin proponents are probably right to point out that it least it FEELS like a massive double standard that proposed cheap medication like ivermectin get severely more scrutinized by the scientific community (like leaving no stone unturned, receiving sherlock holmes levels of investigation), while new expensive "big pharma" medication gets seemingly waved through after the companies own funded trials.

Maybe i am oversimplifying a bit here. But i can understand where they are coming from.

Expand full comment

See your point. I'm a big believer in common sense (naturally my own type of common sense ;-) ) and I'm trusting way more into the concept of vaccination, researchers developing and huge organisations bringing the vaccines into reality much much more then some *insert random prejudice and swearing about the cohort of people if see more and more as dumb a*)

That said: I learned over the years that in the end its all about trust into certain people and systems. All our high IQs, information, research and much much more counts nothing. In the end its about trusting or not trusting.

Good and bad at the same time.

Expand full comment

I wonder if people taking benzos will be able to take this. The enzyme inhibitor they include in the drug is responsible for clonazepam metabolism.

Expand full comment

The enzyme that is inhibited, rather. Ritonivir inhibits CYP3A

Expand full comment